Rheumatoid Arthritis

Complex MONDO:0008383 Pathograph 34 Show in embeddings browser Autoimmune Disease Inflammatory Arthritis

Rheumatoid arthritis is a systemic autoimmune disease in which loss of tolerance, often heralded by ACPA and rheumatoid factor autoantibodies, targets the synovial membrane. Overproduction of TNF-alpha, IL-1, and IL-6 sustains synovial inflammation, with JAK/STAT and NF-kB signaling and metabolic reprogramming amplifying immune and fibroblast activation. Inflammatory synovial hyperplasia forms an invasive pannus that erodes articular cartilage and underlying bone, producing joint destruction.

Ask OpenScientist

Ask a research question about Rheumatoid Arthritis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🏷

Classifications

Harrison's Chapter

📘

Definitions

OHDSI Phenotype Library: Earliest event of Rheumatoid Arthritis

OHDSI cohort definition that indexes the first ever rheumatoid arthritis event in history, using a concept set spanning condition and observation domains, with cohort exit at the end of continuous observation.

PHENOTYPE_ALGORITHM OMOP CDM (OHDSI)

Earliest event of rheumatoid arthritis

Index on the first RA event in history.

Inclusion criteria

Rheumatoid arthritis concept set (condition + observation) OHDSI RA concept set of 15 concepts used in condition and observation domains.
First occurrence in history Index date is the first RA event in the patient's history.
Cohort exit at end of observation Cohort end is the end of continuous observation.

More specific RA cohort (confirmation)

Requires confirmation to improve specificity.

Inclusion criteria

Rheumatoid arthritis concept set (condition + observation) OHDSI RA concept set of 15 concepts used in condition and observation domains.
Confirming RA event Second RA diagnosis or observation code 31 to 365 days after index.
Cohort exit at end of observation Cohort end is the end of continuous observation.

Notes: Source: OHDSI forum phenotype submission "Rheumatoid Arthritis" (logic description and evaluation notes); imported to the OHDSI Phenotype Library (expected id 858).

◆

Subtypes

Seropositive Rheumatoid Arthritis

Characterized by the presence of rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) antibodies.

Show evidence (1 reference)

PMID:28451788 SUPPORT

"Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation. The presence of autoantibodies in the sera of RA patients has provided many clues to the underlying disease pathophysiology. Based on the presence of several autoantibodies like rheumatoid factor (RF),..."

The literature indicates that RA can be subdivided into seropositive and seronegative types based on the presence of RF and/or ACPAs in the sera of the patients, which supports the given statement.

Seronegative Rheumatoid Arthritis

Absence of both RF and anti-CCP antibodies, but with typical clinical features of RA.

Show evidence (4 references)

PMID:33329548 SUPPORT

"Traditionally, RA is divided into seropositive (SP) and seronegative (SN) disease forms, the latter consisting of an array of unrelated diseases with joint involvement."

This study discusses SN-RA as a form characterized by the absence of anti-citrullinated peptide antibody (ACPA) and rheumatoid factor (RF), supporting the statement.

PMID:3266362 SUPPORT

"We became increasingly concerned with the problem of defining properly patients with seronegative RA. Both the statement of seronegativity with regard to rheumatoid factors (RF), the diagnosis of RA, and particularly the exclusion of cases of seronegative arthritis other than RA were difficult."

This study acknowledges the existence of seronegative RA defined by the absence of RF.

PMID:32678001 PARTIAL

"Rheumatoid arthritis (RA) is classified as seropositive or seronegative, depending on the presence/absence of rheumatoid factor (RF), primarily IgM RF, and/or anti-citrullinated protein antibodies (ACPA), commonly detected using anti-cyclic citrullinated peptide (CCP) assays."

This supports the seronegative classification based on the absence of RF and anti-CCP antibodies but points out the complexity and variability within seronegative RA.

+ 1 more reference

Discussions and Knowledge Gaps

Can the quiescent synovial lining program seen in RA remission be actively induced to suppress pathogenic fibroblast-myeloid niches, or is it only a marker that appears after inflammation has already resolved?

KNOWLEDGE GAP OPEN gap_ra_synovial_lining_quiescence_induction

Attached to

pathophysiology#Synovial Hyperplasia pathophysiology#Inflammatory Cytokine Production pathophysiology#Cartilage and Bone Destruction

The entry captures synovial hyperplasia and cytokine-driven joint destruction, but recent spatial and organoid studies indicate that fibroblast density, EGFR-CREB5 signaling, and myeloid-stromal niches may determine whether the lining adopts a homeostatic or invasive state. A causal experiment would distinguish remission biology that can be therapeutically induced from a passive correlate of low inflammation.

Proposed experiments

Human RA synovial organoid EGFR-CREB5 quiescence induction assay

synovial organoid perturbation experiment

exp_ra_synovial_organoid_egfr_creb5_quiescence

Build 3D human synovial organoids from RA fibroblast-like synoviocyte clusters, blood-derived myeloid precursors, and endothelial cells; tune fibroblast spatial density and inflammatory cytokine exposure; activate or inhibit HB-EGF-EGFR-CREB5 signaling; and test whether a quiescent lining program suppresses invasive, cytokine-producing fibroblast states.

Model systems

Human RA synovial fibroblast-myeloid organoid

Three-dimensional human synovial organoid containing RA fibroblast-like synoviocyte clusters, blood-derived myeloid precursors, and endothelial cells to reproduce lining and sublining niche architecture.

ORGANOID namo:Organoid link

human NCBITaxon:9606

synovial membrane UBERON:0002018

fibroblast-like synoviocyte CL:0000057 macrophage CL:0000235 endothelial cell CL:0000115

Perturbations

HB-EGF-EGFR-CREB5 axis activation or blockade

pathophysiology#Synovial Hyperplasia

Ligand stimulation, EGFR inhibition, and CREB5 activation or knockdown used to test whether proximity-sensing signaling actively specifies quiescent lining fibroblast differentiation.

HBEGF EGFR CREB5

IL-1 beta and TGF-beta inflammatory fibroblast challenge

pathophysiology#Inflammatory Cytokine Production

Cytokine combination used to induce the invasive glycolytic RA-FLS state before or after quiescence-induction perturbations.

cytokine-mediated signaling pathway GO:0019221

TAK1 pathway blockade

pathophysiology#Inflammatory Cytokine Production

TAK1 inhibition used as a comparator for suppressing IL-1 beta/TGF-beta pathogenic fibroblast activation.

MAP3K7

Readouts

Quiescent lining fibroblast differentiation

pathophysiology#Synovial Hyperplasia

PRG4, CLU, and PDPN lining markers versus proliferative fibrotic markers.

spatial transcriptomic profiling immunofluorescence assay

Direction: NEGATIVE

Pathogenic fibroblast invasion and matrix remodeling

pathophysiology#Cartilage and Bone Destruction

MMP, collagen, invasion, and synovial-growth readouts in the organoid matrix.

extracellular matrix organization GO:0030198

invasion assay extracellular matrix immunostaining

Direction: POSITIVE

Myeloid-stromal inflammatory niche state

pathophysiology#Inflammatory Cytokine Production

Macrophage subset composition and FLS cytokine output after quiescence induction.

inflammatory response GO:0006954

single-cell transcriptomic profiling multiplex cytokine profiling

Direction: POSITIVE

Controls

Healthy donor synovial organoid

Matched organoid built from non-RA synovial fibroblast and myeloid compartments.

Low-density fibroblast organoid

Density-control organoid expected to favor proliferative or fibrotic states.

Vehicle-treated RA synovial organoid

RA organoid receiving vehicle rather than EGFR-CREB5 or TAK1 perturbation.

Decision criterion

Active induction is supported if EGFR-CREB5 activation restores PRG4/CLU/ PDPN lining markers and reduces invasive, glycolytic, and cytokine readouts even under IL-1 beta/TGF-beta challenge; passive-marker status is supported if quiescent markers appear only after inflammatory signals are removed.

Would support

pathophysiology#Synovial Hyperplasia pathophysiology#Inflammatory Cytokine Production

Would refute

pathophysiology#Synovial Hyperplasia

Show evidence (3 references)

PMID:41427340 SUPPORT In Vitro

"Perturbation of the EGFR-CREB5 axis abolishes fibroblast proximity-sensing and blocks synovial lining fibroblast differentiation."

Provides the specific proximity-sensing pathway that the proposed organoid experiment would test as an inducible remission mechanism.

PMID:41333404 SUPPORT In Vitro

"These organoids reproduced key synovial tissue features, including lining and sublining architecture and stromal-myeloid cell cluster composition."

Supports feasibility of a human synovial organoid that preserves the tissue architecture needed to test lining-state restoration.

+ 1 more reference

How do hypoxic microenvironment signals initiate glycolytic reprogramming in RA synovial cells, and via what epigenetic and inflammatory mechanisms does lactate accumulation and lactylation drive synovial hyperplasia, pannus formation, and osteoclastic bone destruction?

KNOWLEDGE GAP OPEN gap_ra_hypoxia_glycolysis_lactate_axis

Attached to

pathophysiology#Inflammatory Cytokine Production pathophysiology#Synovial Hyperplasia pathophysiology#Cartilage and Bone Destruction

RA synovitis is characterized by a hypoxic microenvironment driven by chronic inflammation, increased metabolic demand, and impaired oxygen diffusion. Recent literature identifies that hypoxia → glycolytic switching → lactate-mediated epigenetic signaling (lactylation) as a conserved axis driving RA pathology. However, the specific causal relationships remain incompletely characterized: (1) which synovial cell types (fibroblasts, macrophages, T cells) are primary targets of hypoxic glycolytic reprogramming, (2) how lactate and lactylation of histone and non-histone proteins modify inflammatory gene expression, and (3) how metabolic reprogramming mechanistically drives the progression from inflammatory cytokine secretion to synovial hyperplasia and invasive pannus formation with subsequent cartilage and bone erosion. The RA entry captures autoimmune and inflammatory cytokine drivers but lacks representation of this metabolic-epigenetic axis as a mechanistic complement to classical immune-centered models, with both conserved cell-intrinsic and synovial-niche implications for targeting either the glycolytic program, lactate metabolism, or lactate-dependent epigenetic rewiring.

Show evidence (1 reference)

PMID:42346149 SUPPORT Other

"In an inflammatory environment, the body's metabolic rate accelerates, leading to increased local oxygen consumption and ultimately creating a hypoxic microenvironment. Research has shown that under hypoxic conditions, glycolysis serves as the body's primary energy pathway and is essential for..."

Recent review articulates the hypoxia-glycolysis-lactylation axis as an incompletely characterized but potentially conserved driver of RA pathology, mechanistically distinct from classical autoimmune pathways.

⚙

Pathophysiology

Autoimmune Response

The immune system mistakenly attacks the body's own tissues, particularly the synovial membrane lining the joints.

Th17 Cell CL:0000899

HLA-DRB1 hgnc:4948 PTPN22 hgnc:9652 CTLA4 hgnc:2505 CD28 hgnc:1653

T-helper 17 type immune response GO:0072538 Inflammatory Response GO:0006954

Show evidence (3 references)

PMID:22608255 SUPPORT

"Rheumatoid arthritis (RA) is an autoimmune disease, characterized by chronic inflammation and synovial hyperplasia in the joints that ultimately lead to cartilage and bone destruction. A wealth of research has shown that CD4(+) T cells, especially IL-17 producing helper T (Th17) cells, play an..."

This reference supports the statement that Th17 cells are involved in the autoimmune response in RA, particularly affecting the joints.

PMID:30572135 SUPPORT

"These pro-inflammatory T-cells are also key players in autoimmunity and a pathogenic role has been demonstrated in several diseases such as rheumatoid arthritis or psoriasis."

The cited literature indicates that Th17 cells play a significant role in the autoimmune response and inflammation characteristic of RA.

PMID:31895885 SUPPORT

"Rheumatoid arthritis (RA) is a prototypic autoimmune disease manifesting as chronic inflammation of the synovium and leading to acceleration of cardiovascular disease and shortening of life expectancy."

This reference corroborates that RA is an autoimmune disease affecting the synovium, aligning with the statement.

Inflammatory Cytokine Production

Overproduction of inflammatory cytokines like TNF-α, IL-1, and IL-6 leads to joint inflammation and damage.

TNF hgnc:11892

cytokine production GO:0001816

synovial membrane UBERON:0002018

Downstream

Centrally Mediated Pain and Central Sensitization Chronic peripheral inflammatory cytokine signaling drives sustained nociceptor input that, over time, promotes central sensitization and centrally mediated pain, which can persist even after peripheral inflammation is controlled.

Show evidence (4 references)

PMID:9836373 PARTIAL

"Rheumatoid arthritis (RA) is well known to be a chronic autoimmune/inflammatory disease which leads to progressive joint damage and destruction."

The abstract explicitly states that RA leads to progressive joint damage and inflammation, which aligns with the statement that overproduction of inflammatory cytokines leads to joint inflammation and damage.

PMID:34688020 SUPPORT

"This pleiotropic cytokine [IL-6] is a key factor in the pathogenesis of rheumatoid arthritis (RA) and is involved in many extra-articular manifestations that accompany the disease."

IL-6 is mentioned as a key factor in the pathogenesis of RA, supporting the notion that overproduction of inflammatory cytokines like IL-6 contributes to RA.

PMID:32830085 PARTIAL

"The pro-inflammatory mediators released via interaction of intracellular kinases direct the development of Rheumatoid arthritis."

The abstract clearly states that pro-inflammatory mediators direct the development of RA, which supports the statement about the role of cytokines like TNF-α, IL-1, and IL-6 in joint inflammation and damage.

+ 1 more reference

Inflammatory-Induced Hypoxic Microenvironment

Chronic synovial inflammation creates a local hypoxic microenvironment as inflammatory cells accelerate oxygen consumption. This synovial hypoxia, in turn, sustains the inflammatory state by inducing metabolic reprogramming toward glycolysis in immune and stromal cells, establishing a feed-forward loop between inflammation, hypoxia, and metabolic dysfunction.

Macrophage CL:0000235 T cell CL:0000084

Response to hypoxia GO:0001666

synovial membrane UBERON:0002018

Downstream

Glycolytic Reprogramming of Inflammatory Cells Hypoxic conditions in the inflamed synovium trigger metabolic reprogramming toward glycolysis as the primary energy pathway to sustain inflammatory cell function.

Show evidence (1 reference)

PMID:42346149 SUPPORT Other

"In an inflammatory environment, the body's metabolic rate accelerates, leading to increased local oxygen consumption and ultimately creating a hypoxic microenvironment."

Paper directly establishes that chronic inflammation in RA creates local synovial hypoxia through increased oxygen consumption.

Glycolytic Reprogramming of Inflammatory Cells

Hypoxia-inducible factors reprogram inflammatory immune cells and synovial fibroblasts toward glycolytic metabolism. Glycolysis becomes the primary ATP-generating pathway, driving sustained production of pro-inflammatory cytokines and matrix-degrading enzymes that maintain synovial hyperplasia and bone destruction.

Macrophage CL:0000235 Fibroblast CL:0000057 T-helper 17 cell CL:0000899

Glycolytic process GO:0006096

synovial membrane UBERON:0002018

Downstream

Inflammatory Cytokine Production Glycolytic reprogramming supports sustained cytokine production and inflammatory signaling in immune and stromal cells.

Lactate-Mediated Signaling and Epigenetic Modification Glycolysis generates lactate, which serves both as a metabolic signaling molecule and as a substrate for post-translational modifications that enhance inflammatory gene expression.

Show evidence (1 reference)

PMID:42346149 SUPPORT Other

"Research has shown that under hypoxic conditions, glycolysis serves as the body's primary energy pathway and is essential for sustaining the inflammatory response."

Paper establishes glycolysis as essential for sustaining RA-associated inflammatory responses in hypoxic synovial conditions.

Lactate-Mediated Signaling and Epigenetic Modification

Lactate produced by glycolytic reprogramming functions as both a metabolic byproduct and a precursor molecule for protein and histone lactylation, driving epigenetic modifications that promote inflammatory gene expression programs and contribute to synovial hyperplasia, pannus formation, and bone destruction. Lactate also activates metabolic signaling pathways in immune and stromal cells to amplify inflammatory responses.

Macrophage CL:0000235 Fibroblast CL:0000057

Epigenetic regulation of gene expression GO:0040029 Histone lactylation GO:0018205 Cytokine production GO:0001816

synovial membrane UBERON:0002018

Downstream

Synovial Hyperplasia Lactate-mediated epigenetic modifications and metabolic signaling promote synovial cell proliferation and inflammatory activation driving synovial hyperplasia.

Cartilage and Bone Destruction Lactate-dependent epigenetic changes enhance production of matrix-degrading enzymes and RANKL signaling in osteoclasts, driving progressive cartilage and bone destruction.

Show evidence (2 references)

PMID:42346149 SUPPORT Other

"lactate, a byproduct of glycolysis, functions not only as a metabolic byproduct but also as a precursor molecule; through lactylation, it contributes to the progression of RA."

Paper establishes lactate-mediated lactylation as a key mechanism linking glycolytic reprogramming to RA progression and joint pathology.

PMID:42346149 SUPPORT Other

"the relationship between glycolysis and synovial hyperplasia, Pannus formation, and bone destruction in RA"

Paper directly links glycolytic reprogramming and its lactate products to the three major pathological features of RA.

Synovial Hyperplasia

The synovial membrane becomes thickened and inflamed, leading to the formation of pannus tissue that invades cartilage and bone.

Synoviocyte CL:0000214 Macrophage CL:0000235

synovial membrane UBERON:0002018

Downstream

Cartilage and Bone Destruction Synovial hyperplasia and pannus formation lead to progressive destruction of articular cartilage and bone.

Show evidence (3 references)

PMID:15353290 SUPPORT

"Rheumatoid arthritis (RA) is a chronic inflammatory disease with progressive articular damage. Activated cells of the synovium produce pro-inflammatory and matrix-degrading effector molecules, which maintain the inflammation and lead to the destruction of the involved joints. In addition to..."

The literature describes that fibroblast-like synoviocytes and macrophages play a key role in the inflammation and invasion of cartilage and bone in RA, supporting the statement.

PMID:35958604 PARTIAL

"Synovial hyperplasia often presents when joints become inflamed due to immune cell infiltration. Synovial membrane... interact with synovial fibroblasts (SFs), T cells, B cells, and other inflammatory cells to promote the production of a variety of pro-inflammatory cytokines and chemokines, such..."

This source confirms the role of synovial fibroblasts and macrophages in the inflammatory process associated with synovial hyperplasia in RA.

PMID:29287304 SUPPORT

"Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by destructive hyperplasia of the synovium. Fibroblast-like synoviocytes (FLS) are a major component of synovial pannus and actively participate in the pathologic progression of RA."

The source supports the role of fibroblast-like synoviocytes in the hyperplasia of the synovium and formation of pannus tissue in RA.

Cartilage and Bone Destruction

Chronic inflammation and pannus formation lead to the erosion of articular cartilage and underlying bone.

synovial joint UBERON:0002217 articular cartilage UBERON:0010996

Show evidence (4 references)

PMID:28597065 SUPPORT

"Structural damage of cartilage and bone tissue is a hallmark of rheumatoid arthritis (RA). The resulting joint destruction constitutes one of the major disease consequences for patients... These factors result in an inflammatory milieu in the affected joints which leads to an increased..."

PMID:17634141 PARTIAL

"Chronic inflammatory arthritis not only leads to inflammatory bone loss but it also involves local erosion of articular bone. This osteo-destructive feature of chronic inflammatory arthritis is a major cause of disability in patients with rheumatoid arthritis."

PMID:24217093 SUPPORT

"Rheumatoid arthritis (RA) is a chronic inflammatory disease characterised by joint swelling, joint tenderness and destruction of synovial joints, leading to severe disability."

+ 1 more reference

JAK/STAT Signaling

The JAK/STAT pathway serves as a central conduit for IL-6 and interferon signaling, driving both immune cell activation and stromal responses in synovium.

Fibroblast CL:0000057 Macrophage CL:0000235

STAT4 hgnc:11365 IL6R hgnc:6019 TYK2 hgnc:12440 STAT3 hgnc:11364

cytokine-mediated signaling pathway GO:0019221

synovial membrane UBERON:0002018

Show evidence (1 reference)

PMID:35367240 SUPPORT

"the JAK-STAT pathway has been majorly implicated in RA disease progression upon IL-6 stimulation"

This review demonstrates that JAK-STAT signaling is central to IL-6 mediated pathogenesis in rheumatoid arthritis, and that JAK inhibitors are clinically effective in treating RA by abrogating this signaling pathway.

NF-κB Activation

NF-κB transcriptional activation drives proinflammatory cytokine production and cell survival signals in immune and fibroblast cells.

Fibroblast CL:0000057 Macrophage CL:0000235

TNFAIP3 hgnc:11896 REL hgnc:9954

immune response GO:0006955 cytokine production GO:0001816

Neutrophil Extracellular Trap Formation

Neutrophils release extracellular traps containing citrullinated histones and autoantigens via PAD4-mediated citrullination, amplifying autoimmunity.

Neutrophil CL:0000775

PADI4 hgnc:18368

immune response GO:0006955

B Cell and Plasma Cell Responses

B cells and plasma cells generate autoantibodies (ACPA, RF) locally within synovium and at mucosal sites, forming ectopic lymphoid structures.

B cell CL:0000236 Plasma cell CL:0000786

PRDM1 hgnc:9346

synovial membrane UBERON:0002018

Mucosal Origins and Dysbiosis

Aberrant immune activation in lung, oral, and gut mucosa precedes systemic autoimmunity, driven by dysbiosis, epithelial barrier dysfunction, and local citrullination.

PADI2 hgnc:18341

respiratory system mucosa UBERON:0004785 oral mucosa UBERON:0003343 intestinal mucosa UBERON:0001242

Epigenetic Dysregulation of T Cell Function

Aberrant chromatin remodeling and histone modifications alter T cell gene expression programs, promoting autoreactive T cell activation and loss of immune tolerance. Changes in DNA methylation and histone acetylation at immune gene loci contribute to disease susceptibility and chronicity.

T-helper 17 cell CL:0000899 CD4-positive helper T cell CL:0000492

SATB1 hgnc:10541

Chromatin Remodeling GO:0006338 Epigenetic Regulation of Gene Expression GO:0040029 T Cell Differentiation GO:0030217

Downstream

Autoimmune Response Epigenetic dysregulation promotes autoreactive T cell programs that drive the autoimmune response

Synovial Cellular Heterogeneity

Single-cell and mass cytometry profiling reveals discrete synovial fibroblast and macrophage subsets with distinct inflammatory and destructive potential. Disease-specific cellular phenotypes enable stratification into responder and non-responder groups for targeted therapy. Integration of synovial multi-omics signatures with clinical data supports precision medicine approaches.

Synovial Fibroblast CL:0000214 Synovial Macrophage CL:0000235 T cell CL:0000084

Leukocyte activation in immune response GO:0002366

synovial membrane UBERON:0002018

Downstream

Cartilage and Bone Destruction Distinct pathogenic fibroblast and macrophage subsets in the inflamed synovium drive cartilage and bone destruction via their respective inflammatory and matrix-degrading programs.

Show evidence (2 references)

PMID:42167060 SUPPORT Human Clinical

"Cellular and molecular deconvolution of synovial tissue heterogeneity reveals discrete disease phenotypes, enabling disease stratification and response prediction. Recent advances in single-cell RNA sequencing and mass cytometry have defined more refined synovial molecular signatures and..."

This review demonstrates that single-cell and multi-omics profiling of synovial tissue reveals discrete cellular phenotypes that correlate with disease pathogenesis and treatment response, supporting precision medicine approaches in RA.

PMID:42167060 SUPPORT Human Clinical

"Despite the success of targeted therapies in rheumatoid arthritis, the lack of predictive biomarkers of response leads to an empirical treatment approach, often delaying effective intervention due to non-response to the initially selected individualized medication regimens in approximately 40%..."

Treatment response heterogeneity in RA is partially explained by differences in synovial cellular and molecular phenotypes, highlighting the need for biomarker-driven precision medicine strategies.

Centrally Mediated Pain and Central Sensitization

Persistent pain in RA occurs despite inflammatory control in a subset of patients, reflecting central sensitization with augmented pain signal processing and impaired descending pain inhibition. Widespread pain phenotype with reduced conditioned pain modulation indicates involvement of central nervous system pain amplification mechanisms. Psychological distress is a stronger predictor of pain severity than peripheral inflammatory markers, supporting mechanism-based pain stratification and targeted analgesic strategies. Central amplification is mediated by dorsal horn neuron hyperexcitability and microglial neuroinflammation in the central nervous system.

Dorsal horn neuron CL:0005000 Microglial cell CL:0000129

Pain Processing GO:0048265 ↑ INCREASED Synaptic Transmission GO:0007268 ↕ DYSREGULATED

central nervous system UBERON:0001017

Show evidence (6 references)

PPR:PPR1260392 SUPPORT Human Clinical

"Four phenotypes were identified: a peripheral, low-inflammation/low-central phenotype (38%); a predominantly inflammatory phenotype (7%); and moderate (43%) and severe (12%) centrally mediated phenotypes. Centrally mediated phenotypes reported the highest pain (NRS 8.2), worst disease impact and..."

Latent profile analysis identified centrally mediated pain phenotypes (moderate and severe) representing 55% of RA patients with persistent pain, showing highest pain severity and worst functional outcomes.

PPR:PPR1260392 SUPPORT Human Clinical

"Conditioned pain modulation was impaired relative to controls (p<0.001) and most reduced in the severe centrally mediated phenotype."

Impaired descending pain inhibition (reduced conditioned pain modulation) is a hallmark of central sensitization and is most pronounced in severe centrally mediated pain phenotype.

PPR:PPR1260392 SUPPORT Human Clinical

"Psychological distress was the strongest independent predictor of pain severity (model R²=0.33), whereas inflammatory markers were not."

Psychological factors are stronger predictors of pain severity than peripheral inflammatory markers in RA, indicating that pain phenotyping requires assessment beyond inflammation.

+ 3 more references

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Blood 1

Anemia of Chronic Disease FREQUENT Anemia HP:0001903

Normochromic normocytic anemia driven by IL-6/hepcidin axis; prevalence 33-60%

Show evidence (2 references)

PMID:15050886 SUPPORT

"Anemia is a common comorbidity in individuals with rheumatoid arthritis (RA). In fact, anemia of the type characterized by low serum iron concentrations in conjunction with adequate iron stores is frequently associated with RA and has served as a model for anemia of chronic disease."

Systematic review reports 33-60% prevalence of anemia in RA, establishing it as a frequent comorbidity.

PMID:20851655 SUPPORT

"Rheumatoid anemia is a typical example of anemia of chronic disease."

Review establishes rheumatoid anemia as the prototypical anemia of chronic disease, mediated by IL-6 and hepcidin.

Cardiovascular 6

Sicca Syndrome OCCASIONAL Keratoconjunctivitis sicca HP:0001097

Dry eyes and mouth due to secondary Sjogren's syndrome

Show evidence (2 references)

PMID:33346115 PARTIAL

"Secondary Sjögren's syndrome and pulmonary manifestations are observed in almost 10% of patients, also in the early disease"

The statement claims that Sicca Syndrome (secondary Sjogren's syndrome) is an occasional extra-articular manifestation of Rheumatoid Arthritis. However, the literature indicates that it occurs in almost 10% of RA patients, suggesting it is not merely occasional but more common.

PMID:27424016 PARTIAL

"Our results demonstrated that the prevalence of sSS was 5.9% (CI:0.6%-10.5%). Number of 27.7% of RA patients positively responded to at least one question about sicca symptoms."

The study found that secondary Sjogren's syndrome (sSS) has a prevalence of 5.9% among RA patients, and 27.7% of RA patients reported sicca symptoms. This indicates that sSS is not just an occasional manifestation but occurs with a higher frequency.

Pericarditis OCCASIONAL Pericarditis HP:0001701

Inflammation of the pericardium

Show evidence (2 references)

PMID:33216192 PARTIAL

"Pericarditis is the term for inflammatory involvement of the pericardium, which can be associated with pericardial effusion and myocardial involvement (perimyocarditis). Pericarditis can be present in the context of systemic inflammatory rheumatic diseases but can also constitute a distinct..."

This reference confirms that pericarditis can be present in systemic inflammatory rheumatic diseases, including rheumatoid arthritis, indicating it can occur as a cardiovascular manifestation.

PMID:11055006 SUPPORT

"Pericardial effusion is common in patients with rheumatoid arthritis. It is essentially a sign of pericardial involvement of the rheumatoid disease."

This reference directly states that pericardial effusion, which is indicative of pericarditis, is common in rheumatoid arthritis patients, supporting the statement.

Vasculitis OCCASIONAL Vasculitis HP:0002633

Rheumatoid vasculitis affecting small and medium vessels; associated with seropositive, long-standing disease

Show evidence (1 reference)

PMID:33609792 SUPPORT

"Central and peripheral nervous system involvement is usually due to small vessel vasculitis, joint damage, or drug toxicity."

Small vessel vasculitis is recognized as a cause of neurological and other extra-articular manifestations in RA.

Raynaud Phenomenon OCCASIONAL Raynaud phenomenon HP:0030880

Vasospastic episodes in digits; may indicate underlying vasculitis

Lymphadenopathy OCCASIONAL Lymphadenopathy HP:0002716

Reactive lymph node enlargement reflecting systemic immune activation

Myocardial infarction Myocardial infarction HP:0001658

Show evidence (1 reference)

PMID:33609792 SUPPORT Human Clinical

"patients with RA have twice the risk of myocardial infarction"

This review of RA extra-articular disease states patients have twice the risk of myocardial infarction.

Eye 2

Scleritis OCCASIONAL Scleritis HP:0100532

Inflammation of the sclera of the eye

Show evidence (4 references)

PMID:20559644 SUPPORT

"The main spectrum of eye involvement comprises keratoconjunctivitis sicca, episcleritis and scleritis as well as ulcerative keratitis."

This reference indicates that scleritis is part of the spectrum of eye involvement in rheumatoid arthritis, supporting the statement.

PMID:37344292 SUPPORT

"Rheumatoid arthritis and systemic vasculitides, particularly antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides, are the main autoimmune causes of scleritis and episcleritis."

This reference supports that scleritis is associated with rheumatoid arthritis.

PMID:30412434 SUPPORT

"Rheumatoid arthritis and Wegener granulomatosis were the 2 most common systemic associations among our cohort."

This reference confirms that rheumatoid arthritis is a common systemic association with scleritis.

+ 1 more reference

Episcleritis OCCASIONAL Episcleritis HP:0100534

Inflammation of the episcleral tissue; less severe than scleritis

Metabolism 2

Joint Swelling VERY_FREQUENT Joint swelling HP:0001386

Synovial hypertrophy and effusion leading to joint swelling

Pleural Effusion OCCASIONAL Pleural effusion HP:0002202

Exudative pleural effusion with low glucose and high LDH

Show evidence (1 reference)

PMID:33609792 SUPPORT

"The second major cause of death in patients with RA is respiratory disease, which occurs in 30-40% of patients. RA may affect the lung interstitium, airways, and pleurae"

Pleural involvement is explicitly listed among the respiratory manifestations of RA.

Musculoskeletal 8

Symmetric Polyarthritis VERY_FREQUENT Symmetric polyarthritis HP:0040311

Sequelae: Joint Deformity Reduced Mobility

Show evidence (3 references)

PMID:37410796 SUPPORT

"Incident RA presents mainly as symmetric arthritis."

This literature clearly supports that RA often presents as symmetric arthritis, aligning with the statement.

PMID:37158761 SUPPORT

"Symmetrical involvement of the hand joints is described as characteristic of rheumatoid arthritis (RA)."

This reference reinforces that symmetric polyarthritis is characteristic of RA, supporting the statement.

PMID:22035393 PARTIAL

"Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder affecting multiple organ systems, joints, ligaments, and bones and commonly involves the cervical spine."

While this reference mentions systemic and joint involvement, it does not specifically address symmetric polyarthritis or its frequency.

Morning Stiffness FREQUENT Generalized morning stiffness HP:0005197

Show evidence (2 references)

PMID:26403254 SUPPORT Other

"In patients with rheumatoid arthritis (RA), morning stiffness is linked more to functional disability and pain than disease activity, as assessed by joint counts and markers of inflammation."

Expert-panel consensus stating that morning stiffness is a clinically important RA symptom, more closely tied to disability and pain than to measured disease activity.

PMID:36544060 SUPPORT

"Rheumatoid arthritis symptoms follow a 24 h circadian rhythm and exhibit high thresholds of pain, functional disability, and stiffness predominantly early in the morning."

This excerpt confirms that morning stiffness is a frequent and notable symptom in rheumatoid arthritis, aligning with the frequency and naming attributes in the statement.

Joint Deformity FREQUENT Abnormal joint morphology HP:0001367

Erosive Arthritis FREQUENT Arthritis HP:0001369

Bone erosions visible on radiography, particularly in hands and feet

Flexion Contracture FREQUENT Flexion contracture HP:0001371

Fixed flexion deformity of joints due to chronic synovitis and fibrosis

Cervical Spine Instability OCCASIONAL Atlantoaxial instability HP:0003467

Atlantoaxial subluxation due to pannus erosion of the transverse ligament; can compromise the spinal cord. Cervical spine involvement of any kind is reported in up to 80% of RA patients, while symptomatic atlantoaxial instability is considerably less common.

Show evidence (2 references)

PMID:25151973 SUPPORT

"Rheumatoid arthritis (RA) is a systemic chronic inflammatory disorder that can compromise the cervical spine in up to 80% of the cases."

Systematic review demonstrates high prevalence of cervical spine involvement in RA, with atlantoaxial subluxation being the most common form.

PMID:33609792 SUPPORT

"screening for depression, anxiety, atlantoaxial instability, and atherosclerosis"

Atlantoaxial instability is listed as a screening target in RA management, confirming its clinical significance.

Muscle Weakness FREQUENT Muscle weakness HP:0001324

Disuse atrophy and inflammatory myopathy contributing to functional disability

Osteoporosis FREQUENT Osteoporosis HP:0000939

Generalized bone loss due to systemic inflammation and glucocorticoid use

Show evidence (1 reference)

PMID:33199321 SUPPORT

"Both inflammation and corticosteroids, however, have an adverse effect on bone mineral density, potentially resulting in osteoporosis and an increased risk of fractures."

Review confirms that RA patients face osteoporosis from both systemic inflammation and corticosteroid therapy.

Nervous System 2

Reduced Mobility FREQUENT Gait disturbance HP:0001288

Peripheral Neuropathy OCCASIONAL Peripheral neuropathy HP:0009830

Sensorimotor neuropathy from vasculitis of the vasa nervorum

Show evidence (2 references)

PMID:24331794 SUPPORT

"They are common in patients with primary systemic vasculitis and are seen in vasculitis secondary to disorders such as rheumatoid arthritis, viral infections, and diabetic inflammatory neuropathies."

Vasculitic neuropathies are explicitly noted in RA as secondary vasculitis.

PMID:33609792 SUPPORT

"Central and peripheral nervous system involvement is usually due to small vessel vasculitis, joint damage, or drug toxicity."

Peripheral nervous system involvement in RA is attributed to vasculitis and structural damage.

Respiratory 2

Interstitial Lung Disease OCCASIONAL Abnormal pulmonary interstitial morphology HP:0006530

Show evidence (3 references)

PMID:15163106 PARTIAL

"Extra-articular RA (ExRA) includes a wide variety of disease manifestations... ExRA manifestations are not uncommon, explain excess mortality in RA and are predicted by smoking and autoantibodies."

The reference confirms that extra-articular manifestations in RA are common, but does not specifically address the frequency of interstitial lung disease.

PMID:38411210 PARTIAL

"RA-associated interstitial lung disease (RA-ILD) is a major contributor to mortality, with no decline in incidence and scant therapeutic options."

The reference confirms RA-ILD as a significant extra-articular manifestation, but it does not detail its specific frequency.

PMID:31376890 PARTIAL

"The most common intrathoracic manifestations of RA include interstitial lung disease, airway disease, pleural disease, rheumatoid nodules, and drug-induced toxicity."

The reference indicates that interstitial lung disease is a common pulmonary manifestation of RA, but does not quantify how often it occurs.

Pleuritis Pleuritis HP:0002102

Show evidence (1 reference)

PMID:33609792 SUPPORT Human Clinical

"RA may affect the lung interstitium, airways, and pleurae"

The review notes RA may affect the pleurae, supporting pleuritis.

Constitutional 1

Fatigue FREQUENT Fatigue HP:0012378

Show evidence (3 references)

PMID:25005390 SUPPORT

"Many of these people experience pain, inflammation, stiffness, reduced mobility and joint function, and fatigue."

The literature supports that fatigue is a common symptom experienced by people with rheumatoid arthritis.

PMID:26803313 PARTIAL Other

"Fatigue occurs in all chronic inflammatory diseases, in cancer, and in some neurological conditions."

Places fatigue in the class of chronic inflammatory diseases to which RA belongs; the snippet does not address RA specifically, so support is PARTIAL.

PMID:38643104 PARTIAL

"Patients with RA reported worse outcomes for all PROMs than those with CSA or UA."

This study highlights the high burden of fatigue among patients with RA, supporting fatigue as a common systemic phenotype.

Other 8

Rheumatoid Nodules OCCASIONAL Rheumatoid nodule HP:6000418

Show evidence (6 references)

PMID:15163106 SUPPORT

"Extra-articular RA (ExRA) includes a wide variety of disease manifestations... ExRA manifestations are not uncommon, explain excess mortality in RA and are predicted by smoking and autoantibodies."

The abstract mentions that extra-articular manifestations are not uncommon in RA, suggesting that these phenotypes occur occasionally.

PMID:17544962 SUPPORT

"Rheumatoid nodules are the most common extra-articular manifestation of rheumatoid arthritis."

Rheumatoid nodules are identified as the most common extra-articular manifestation, reinforcing their occurrence in RA.

PMID:27151711 SUPPORT

"Rheumatoid nodules (RNs) are one of the most frequent extra-articular manifestations of RA."

The abstract indicates that rheumatoid nodules are among the most frequent extra-articular manifestations, supporting their occasional presence as noted in the given statement.

+ 3 more references

Boutonniere Deformity FREQUENT

Flexion contracture of PIP joint with hyperextension of DIP joint

Show evidence (3 references)

PMID:2661577 SUPPORT

"The pathology of the boutonniere begins with a synovitis of the joint, followed by elongation al the central slip, subluxation of the later bands, and contracture of the retinacular ligaments."

The reference describes the occurrence of boutonniere deformity in the context of rheumatoid arthritis, supporting the statement that it is a frequent musculoskeletal issue associated with this condition.

PMID:34628456 SUPPORT

"Bone erosion can be observed at the DIP joint in patients with RA, and these cases frequently shows bone erosions of other finger joints, such as PIP joint."

The study indicates that bone erosions, including those leading to deformities like boutonniere, are common in rheumatoid arthritis patients.

PMID:19474183 SUPPORT

"The average working space volume was 4921 cc in rheumatoid patients with no visible hand deformity and 1154 cc in the presence of combined finger deformities (P < 0.005)."

This reference discusses the prevalence of hand deformities in rheumatoid arthritis, indicating that such deformities, including boutonniere, significantly impact the working space of the hand.

Swan-neck Deformity OCCASIONAL Swan neck-like deformities of the fingers HP:0006150

Hyperextension of PIP joint with flexion of DIP joint

Show evidence (1 reference)

PMID:2661576 SUPPORT

"It is important to evaluate each swan-neck deformity to determine the mobility and radiographic condition of the PIP joint."

The reference discusses the evaluation and treatment of swan-neck deformity in the context of rheumatoid arthritis, supporting the association between rheumatoid arthritis and swan-neck deformity.

Felty's Syndrome OCCASIONAL

Combination of rheumatoid arthritis, splenomegaly, and neutropenia

Show evidence (3 references)

PMID:1862580 SUPPORT

"Felty's syndrome (FS) consists of the triad: rheumatoid arthritis (RA), leukopenia and splenomegaly. FS occurs in approximately 1% of patients with RA."

The literature confirms that Felty's Syndrome is a hematologic condition associated with rheumatoid arthritis, occurring occasionally (approximately 1% of patients with RA).

PMID:12455813 SUPPORT

"The hematological manifestations can be conveniently categorized into the broad areas of; anemia, particularly NSAID induced iron deficiency anemia and the anemia of chronic disease, neutropenia, particularly Felty's syndrome and the large granular lymphocyte syndrome and drug induced neutropenia."

The literature supports that Felty's Syndrome is a hematologic manifestation of rheumatoid arthritis, occurring occasionally.

PMID:312016 SUPPORT

"Thus, patients with rheumatoid arthritis without overt splenic enlargement may have pathophysiologic Felty's syndrome, and in vitro studies such as these may be used to define this process."

The literature supports that Felty's Syndrome is associated with rheumatoid arthritis, even in the absence of splenomegaly, indicating it as a hematologic condition.

Tenosynovitis FREQUENT Tenosynovitis HP:6001438

Inflammation of tendon sheaths, particularly in wrists and fingers; may precede joint erosion

Show evidence (1 reference)

PMID:28460018 SUPPORT

"MRI-detected tenosynovitis was associated with RA development independent of other types of MRI-detected inflammation [odds ratio (OR) = 7.5, 95% CI: 2.4, 23]"

Study demonstrates tenosynovitis is independently associated with RA development (OR 7.5), confirming it as a key early feature.

Carpal Tunnel Syndrome OCCASIONAL Entrapment neuropathy HP:0012181

Median nerve compression from wrist synovitis and tenosynovitis

Show evidence (1 reference)

PMID:39343950 SUPPORT

"Our results showed that RA patients have a higher risk of getting CTS regardless of whether the ebi database (IVW, OR = 1.045, 95% CI: 1.016-1.075, P = 0.002) or the GEO database (IVW, OR = 1.001, 95% CI: 1.001-1.002, P = 0.001) is selected for CTS data."

Mendelian randomization confirms causal relationship between RA and increased carpal tunnel syndrome risk.

Accelerated Atherosclerosis FREQUENT Accelerated atherosclerosis HP:0004943

Chronic inflammation drives premature cardiovascular disease; RA patients have 2x risk of myocardial infarction

Show evidence (1 reference)

PMID:33609792 SUPPORT

"Cardiovascular (CV) disease is the most common cause of death in patients with RA. Compared to the general population, patients with RA have twice the risk of myocardial infarction and up to 50% increased CV mortality risk."

Review quantifies the excess cardiovascular risk in RA as 2-fold for MI and 50% increased CV mortality.

Interstitial pneumonitis Interstitial pneumonitis HP:0006515

Show evidence (1 reference)

PMID:33609792 SUPPORT Human Clinical

"RA may affect the lung interstitium, airways, and pleurae"

The review notes RA may affect the lung interstitium, supporting interstitial pneumonitis.

🧬

Genetic Associations

HLA-DRB1 (Associated with increased risk)

Show evidence (7 references)

PMID:24447879 SUPPORT

"HLA-DRB1*04 was found to have increased frequency in the RA group compared to controls (P < 0.001, OR = 3.14)...HLA-DRB1*04:05 was associated with RA (P = 0.005, OR = 3.41)"

The study shows an increased frequency of HLA-DRB1*04 and HLA-DRB1*04:05 in the RA group, indicating an association with increased risk.

PMID:32638005 SUPPORT

"This review identifies the most significant genetic variants associated with RA susceptibility to date, with particular focus on the contribution of the HLA class II genes across different ethnic groups."

The review discusses the significant role of HLA-DRB1 in RA susceptibility.

PMID:16542468 SUPPORT

"HLA-DR alleles such as HLA-DR4 and HLA-DR1 are associated with the risk to develop RA."

HLA-DR4, a subtype of HLA-DRB1, is associated with an increased risk of developing RA.

+ 4 more references

PTPN22 (Associated with increased risk)

Show evidence (3 references)

PMID:30957405 SUPPORT

"The overall effect of PTPN22-1123 on RA risk in all genetic random models showed significant positive associations."

The study found significant positive associations between PTPN22 genetic variations and increased risk of rheumatoid arthritis.

PMID:15790351 SUPPORT

"A functional variant (R620W) of the intracellular protein tyrosine phosphatase N22 (PTPN22) has now been conclusively shown to confer approximately two-fold risk for seropositive RA as well as several other autoimmune disorders."

The variant R620W of PTPN22 is associated with a significantly increased risk of rheumatoid arthritis.

PMID:15838240 SUPPORT

"The second risk factor for rheumatoid arthritis, the PTPN22 polymorphism, has been identified."

The PTPN22 polymorphism has been identified as a genetic risk factor for rheumatoid arthritis.

STAT4 (Associated with increased risk)

Show evidence (2 references)

PMID:30864557 SUPPORT

"Herein, we found a significant positive association between minor T allele as well as different genotypes with the risk of RA."

The study found a significant positive association between the STAT4 gene rs7574865 SNP and the risk of rheumatoid arthritis (RA).

PMID:20453440 SUPPORT

"We and other investigators also found that IRF5, STAT4 and BLK are associated not only with SLE, but also rheumatoid arthritis and systemic sclerosis."

The literature supports an association between the STAT4 gene and increased risk of rheumatoid arthritis.

CTLA4 (Associated with increased risk)

Show evidence (3 references)

PMID:34339393 SUPPORT

"This meta-analysis confirmed that rs3087243 and rs231775 polymorphism were associated with the risk of RA in both overall population and ethnic-specific analysis, but there was no association between rs5742909 polymorphism and RA risk"

The meta-analysis provides evidence that CTLA-4 gene polymorphisms are associated with an increased risk of rheumatoid arthritis.

PMID:35758965 SUPPORT

"There was a significantly higher median (inter-quartile range) expression of CTLA-4 and CCL2 in RA patients in comparison to controls (P < 0.05)"

The study found significantly higher expression of CTLA-4 in RA patients, supporting the association of CTLA-4 with increased RA risk.

PMID:11196709 SUPPORT

"For most autoimmune disorders... the gene encoding cytotoxic T lymphocyte-associated antigen 4 (CTLA4) has been suggested as a candidate gene for conferring susceptibility to autoimmunity."

The article discusses CTLA4 as a candidate gene for susceptibility to autoimmune diseases, including rheumatoid arthritis.

PADI4 (Associated with increased risk)

Show evidence (1 reference)

PMID:17893996 SUPPORT

"peptidylarginine deiminase (gene name abbreviated to PADI, protein name abbreviated to PAD) type 4 is the one of the non-HLA genetic factors involved in RA via citrullination"

This review identifies PADI4 as a key non-HLA genetic susceptibility factor for RA, demonstrating the link between citrullination of proteins and generation of autoantigens targeted by anti-citrullinated protein antibodies.

PADI2 (Associated with increased risk)

TNF (Central proinflammatory cytokine)

IL6R (Mediates IL-6 signaling)

TYK2 (Associated with increased risk)

BACH2 (GWAS)

TNFAIP3 (GWAS)

STAT3 (GWAS)

IL10 (GWAS)

CD28 (GWAS)

EGR2 (GWAS)

ETS1 (GWAS)

IRF4 (GWAS)

IRF8 (GWAS)

SATB1 (GWAS)

IKZF1 (GWAS)

REL (GWAS)

PRDM1 (GWAS)

IL21R (GWAS)

💊

Medical Actions

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Action: NSAID therapy Ontology label: Pharmacotherapy NCIT:C15986

Agent: NSAID NCIT:C257

Reduce pain and inflammation.

Show evidence (2 references)

PMID:11899747 PARTIAL Human Clinical

"NSAID toxicity mostly affected the GI tract. There was a similar incidence of GI-related adverse events between patients with and patients without GI protection, mainly dyspepsia and nausea. NSAIDs have the potential to cause adverse events in the GI tract."

Characterises the gastrointestinal toxicity that constrains NSAID use; it addresses safety rather than the efficacy claim in this treatment description.

PMID:23083758 PARTIAL Other

"NSAIDs reduce pain and stiffness effectively in most patients, are able to reduce systemic and local inflammation, and can inhibit progression of structural damage in the spine."

Documents NSAID efficacy for pain, stiffness and inflammation, but in spondyloarthritis rather than RA, so support is PARTIAL.

Disease-Modifying Antirheumatic Drugs (DMARDs)

Action: Pharmacotherapy NCIT:C15986

Slow disease progression and prevent joint damage (e.g., methotrexate, hydroxychloroquine).

Show evidence (5 references)

PMID:14969069 SUPPORT

"Disease-modifying anti-rheumatic drugs (DMARDs) used in combination appear to be more effective than monotherapies at reducing the rate of progressive joint damage during randomized controlled trials."

This statement directly supports the idea that DMARDs slow disease progression and prevent joint damage.

PMID:8601050 SUPPORT

"Methotrexate is presently the most popular of the DMARDs for the treatment of rheumatoid arthritis. Methotrexate inhibits dihydrofolate reductase and adenosine release and has a secondary effect on cytokines and polymorphonuclear chemotaxis. It is highly metabolised within cells and remains..."

This excerpt indicates methotrexate's mechanisms in treating RA, affirming its role in slowing disease progression and preventing joint damage.

PMID:25172238 SUPPORT

"According to the results of several head-to-head comparative trials against other synthetic DMARDs, MTX has been recognised as the 'anchor drug' for the treatment of RA."

This confirms methotrexate's effectiveness as a primary treatment in managing RA, thus supporting the statement.

+ 2 more references

Biologics

Action: biologic therapy Ontology label: Immunotherapy NCIT:C15262

Target specific components of the immune system (e.g., TNF-α inhibitors, IL-6 inhibitors).

Show evidence (3 references)

PMID:22166850 SUPPORT

"Rheumatoid arthritis (RA) remains a major clinical problem, but treatments involving biologics have revolutionized its management. They target pathogenically relevant cytokines such as tumor necrosis factor and immune cells such as B cells."

This reference confirms that biologics used in the treatment of RA target specific components of the immune system, including cytokines like TNF-α.

PMID:25697599 SUPPORT

"Anticytokine therapy for inflammatory diseases became a clinical reality with the introduction of tumor necrosis factor (TNF) inhibitors for the treatment of severe rheumatoid arthritis."

The reference highlights that anticytokine therapies, including TNF inhibitors, are used in RA treatment, thus supporting the statement.

PMID:32550671 SUPPORT

"Cytokine blockers were the first to be developed and rapidly expanded. They include agents that act against tumor necrosis factor alpha (TNF-α)... and interleukin (IL) 6 (tocilizumab and sarilumab)."

The reference supports that biologics used for RA treatment include TNF-α inhibitors and IL-6 inhibitors, which target specific components of the immune system.

JAK Inhibitors

Action: Pharmacotherapy NCIT:C15986

Agent: tofacitinib CHEBI:71200

Oral targeted synthetic DMARDs (tofacitinib, baricitinib, upadacitinib, and related agents) that inhibit Janus kinases, blocking JAK/STAT signal transduction downstream of multiple pro-inflammatory cytokine receptors (notably IL-6). Used in rheumatoid arthritis, typically after inadequate response to conventional synthetic or biologic DMARDs.

Mechanism Target:

INHIBITS JAK/STAT Signaling — JAK inhibitors block Janus kinase catalytic activity, suppressing the IL-6-driven JAK/STAT signaling that is implicated in RA synovial inflammation and disease progression.

Show evidence (1 reference)

PMID:35367240 SUPPORT Human Clinical

"This review discusses the history of research into IL-6 biology and therapies that target the IL-6 driven JAK/STAT pathway, including the successes, challenges, and drawbacks, emphasizing RA."

The review frames JAK inhibitors as therapies that target the IL-6-driven JAK/STAT pathway in RA, supporting the INHIBITS link to the JAK/STAT Signaling node.

Show evidence (2 references)

PMID:32550671 SUPPORT Human Clinical

"Janus kinase (JAK) inhibitors (tofacitinib, baricitinib, and upadacitinib) and phosphodiesterase 4 inhibitors (apremilast) form this group."

Identifies tofacitinib, baricitinib, and upadacitinib as the JAK-inhibitor small-molecule class used in systemic autoimmune conditions including RA.

PMID:35367240 SUPPORT Human Clinical

"JAK inhibitors, namely Tofacitinib, Baricitinib, Decernotinib, Upadacitinib, Peficitinib, and Filgotinib, have demonstrated clinical efficacy in recent decades as an alternative therapeutic strategy to abrogate IL-6 mediated aberrant activity in RA."

Establishes that JAK inhibitors have demonstrated clinical efficacy in RA, supporting their inclusion as a targeted synthetic DMARD treatment class.

Glucocorticoids

Action: systemic corticosteroid therapy Ontology label: Systemic Corticosteroid Therapy NCIT:C122080

Potent anti-inflammatory agents used for short-term control of flares or as a bridge therapy.

Show evidence (3 references)

PMID:28043173 PARTIAL

"Glucocorticoids - be it conventional or modified/delayed-release formulations - have so far been convincing in clinical practice, and their widespread use will therefore continue."

The literature supports the use of glucocorticoids for the treatment of rheumatoid arthritis, highlighting their efficacy. However, it does not specify that they are used for short-term control of flares or as bridge therapy, thus only partially supporting the precise conditions mentioned in the statement.

PMID:24527481 PARTIAL

"The family physician plays several important roles in the management of patients with RA by early diagnosis of RA, with initiation of synthetic DMARD therapy, and in long-term follow-up to minimize complications of DMARD therapy and its impact on patient comorbidities."

This reference mentions the management and use of various therapies for rheumatoid arthritis, but it does not explicitly discuss the short-term use or glucocorticoids as bridge therapy, providing only partial support.

PMID:29745893 PARTIAL

"Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and disease-modifying antirheumatic drugs (DMARDs) are widely used to treat RA patients."

This literature confirms the use of corticosteroids (which include glucocorticoids) in treating RA but does not specify their role as short-term or bridge therapy, thereby partially supporting the statement.

Physical Therapy

Action: Physical Therapy NCIT:C15302

Maintains joint mobility and strengthens surrounding muscles.

Show evidence (3 references)

PMID:15266230 SUPPORT

"Physiotherapy and rehabilitation applications significantly augment medical therapy by improving the management of RA and reducing handicaps in daily living for patients with RA."

The literature supports the effectiveness of physiotherapy in managing RA, including maintaining joint mobility and reducing disabilities.

PMID:25748549 SUPPORT

"The exercise programme consisted of six sessions of strengthening and stretching exercises with a hand therapist, daily home exercises and strategies to maximise adherence."

The results indicate that exercise programmes included in physical therapy can be effective in maintaining joint function and strengthening muscles in RA patients.

PMID:9667624 SUPPORT

"The results suggest that dynamic exercise therapy is effective in increasing aerobic capacity and muscle strength."

Dynamic exercise therapy, a component of physical therapy, has been shown to improve muscle strength and maintain physical capacity in RA patients.

🌍

Environmental Factors

Smoking

Increases risk and severity

Show evidence (3 references)

PMID:22609003 SUPPORT

"Smoking is associated with an increased risk of developing seropositive RA (RF and/or ACPA). Recent studies show that tobacco smoking can influence disease phenotype, with the development of more aggressive disease and greater joint damage."

The literature indicates that smoking increases the risk of developing seropositive RA and may lead to more severe disease outcomes, which aligns with the statement.

PMID:12860726 SUPPORT

"In a multivariate analysis the main predictors of severe ExRA were smoking at RA diagnosis (risk ratio (RR)=2.94; 95% confidence interval (95% CI) 1.68 to 5.13)."

This reference indicates smoking as a significant predictor of severe extra-articular manifestations in RA, supporting the statement about severity.

PMID:36155967 SUPPORT

"MUC5B and TOLLIP single nucleotide polymorphisms (SNPs) and cigarette smoking were associated with rheumatoid arthritis-interstitial lung disease (RA-ILD)."

Smoking is listed as a risk factor for RA and its associated complications, such as interstitial lung disease.

Infections

Potential trigger for disease onset

Show evidence (3 references)

PMID:28516867 PARTIAL

"Extensive data supports the roles of genetic, environmental and microbial factors in the triggering and development of this disease. Proteus mirabilis is considered as the main microbial culprit in the causation of RA."

This reference supports the role of infections, specifically microbial factors, as potential environmental triggers for the onset of rheumatoid arthritis.

PMID:32582191 PARTIAL

"In conclusion, we retrieved more than one line of evidence for mucosal sites and different microbial taxa to be potentially involved in the development of RA."

This reference provides multiple lines of evidence suggesting that infections, specifically from various microbial taxa, are potential contributors to the onset of rheumatoid arthritis.

PMID:35897715 PARTIAL

"Possible mechanisms involving environmental and individual factors in RA pathogenesis were analyzed, namely, infections, mental stress, sleep deprivation ecology, age, perinatal and gender factors, eating habits, obesity and smoking."

This reference explicitly includes infections among the environmental factors that may contribute to the onset of RA.

🔬

Biochemical Markers

Rheumatoid Factor (RF) (Positive)

Show evidence (3 references)

PMID:1757925 SUPPORT

"RF represent a key element in the rheumatoid inflammatory process. Their occurrence in preillness specimens suggests that they may have a primary role in the pathogenesis of the disease."

The article indicates that RF is a significant element in the pathogenesis of rheumatoid arthritis, supporting its presence as a positive biochemical marker in seropositive RA.

PMID:34675934 SUPPORT

"The definition of seropositive or seronegative RA is based on the presence or absence of rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPAs)."

The presence of RF is a defining characteristic for distinguishing seropositive RA from seronegative RA.

PMID:26199263 SUPPORT

"We observed significant differences in RF, anti-CCP antibody, CRP, and ESR concentrations between the RA and control groups (P <.01). The sensitivity, specificity, and accuracy in the diagnosis of RA were 91.0%, 74.4%, and 87.0%, respectively, for RF."

RF's sensitivity and specificity in diagnosing RA support the statement about its presence being positive in seropositive RA.

Anti-Cyclic Citrullinated Peptide (anti-CCP) Antibodies (Positive)

Show evidence (7 references)

PMID:20072731 SUPPORT

"A cohort of 937 patients with RA was studied ... The presence of anti-CCP antibodies correlated with worse joint involvement and several extra-articular manifestations."

This study indicates that anti-CCP antibodies are present in patients with RA and correlate with worse joint involvement, supporting the presence of anti-CCP antibodies in seropositive RA.

PMID:31656153 SUPPORT

"RA seronegativity is described as the absence of both RF and ACPA, while seropositivity is recognized by the presence of at least one of the two antibodies."

This study defines seropositive RA as having positive rheumatoid factor and/or anti-citrullinated protein antibodies (ACPA), thus supporting the statement.

PMID:31848495 PARTIAL Human Clinical

"RF and anti-CCP antibodies can be detected in the serum of some PsA patients."

Concerns psoriatic arthritis, not RA; retained only to record that anti-CCP positivity is not wholly specific to RA.

+ 4 more references

Erythrocyte Sedimentation Rate (ESR) (Elevated)

Show evidence (3 references)

PMID:16818462 SUPPORT

"In patients with rheumatoid arthritis who developed heart failure, the proportion with ESR >/=40 mm/h was highest (23%) during the 6-month period immediately preceding the new-onset heart failure, as compared with the average ESR during the entire remaining follow-up period, both before and..."

The study provides evidence that ESR levels are elevated in patients with rheumatoid arthritis, particularly before heart failure onset.

PMID:26199263 SUPPORT

"We observed significant differences in RF, anti-CCP antibody, CRP, and ESR concentrations between the RA and control groups (P <.01)."

The study highlights that ESR is significantly elevated in patients with rheumatoid arthritis compared to the control group.

PMID:34958010 PARTIAL Human Clinical

"ESR was significantly correlated with DVT risk after TKA (OR = 1.844, 95% CI = 1.022-2.981, P = 0.019)."

Shows ESR carries prognostic information after total knee arthroplasty; it does not itself establish that ESR is elevated in RA, so support is PARTIAL.

C-Reactive Protein (CRP) (Elevated)

Show evidence (4 references)

PMID:36539129 PARTIAL

"CRP has been widely accepted as a systemic inflammatory marker."

The reference denotes CRP as an inflammatory marker in rheumatoid arthritis, indicating elevated levels.

PMID:28393498 SUPPORT

"The C-reactive protein (CRP) level and erythrocyte sedimentation rate (ESR) are important disease activity biomarkers in rheumatoid arthritis (RA)."

The reference confirms that CRP levels are significant indicators of disease activity in RA, suggesting they are elevated in such conditions.

PMID:26199263 SUPPORT

"We observed significant differences in RF, anti-CCP antibody, CRP, and ESR concentrations between the RA and control groups (P <.01)."

The study found a significant difference in CRP levels between RA patients and healthy controls, supporting the statement that CRP is elevated in RA.

+ 1 more reference

🔀

Differential Diagnoses

Conditions with similar clinical presentations that must be differentiated from Rheumatoid Arthritis:

Juvenile idiopathic arthritis MONDO:0011429

Overlapping Features JIA is an umbrella term for inflammatory arthritis of unknown cause beginning before age 16 and lasting more than 6 weeks. It is a distinct disease entity rather than a subtype of adult rheumatoid arthritis, and is classified under rheumatic disorder rather than under rheumatoid arthritis. The RF-positive polyarticular form (childhood-onset rheumatoid arthritis) is the subset that shares genetic and clinical features with adult-onset RA, which is the source of the clinical overlap between the two.

Show evidence (2 references)

PMID:35087087 SUPPORT Other

"Juvenile idiopathic arthritis (JIA) is an umbrella term for arthritis of unknown origin, lasting for >6 weeks with onset before 16 years of age."

Defines JIA as a distinct arthritis entity delimited by onset age and duration, separate from adult-onset rheumatoid arthritis.

PMID:37700346 PARTIAL Human Clinical

"Childhood-onset rheumatoid arthritis (CORA), known as rheumatoid factor (RF)-positive juvenile idiopathic arthritis is a type of juvenile idiopathic arthritis that shares the same genetic factors and clinical features as adult-onset rheumatoid arthritis."

Establishes that the RF-positive JIA subset shares genetic and clinical features with adult RA, which is why the two are clinical differentials; it places that subset within JIA, not within RA.

{ }

Source YAML

click to show

name: Rheumatoid Arthritis
creation_date: '2025-12-04T16:57:31Z'
updated_date: '2026-05-21T06:08:04Z'
description: >-
  Rheumatoid arthritis is a systemic autoimmune disease in which loss of tolerance, often heralded by ACPA and rheumatoid factor autoantibodies, targets the synovial membrane.
  Overproduction of TNF-alpha, IL-1, and IL-6 sustains synovial inflammation, with JAK/STAT and NF-kB signaling and metabolic reprogramming amplifying immune and fibroblast activation.
  Inflammatory synovial hyperplasia forms an invasive pannus that erodes articular cartilage and underlying bone, producing joint destruction.
category: Complex
parents:
- Autoimmune Disease
- Inflammatory Arthritis
definitions:
- name: "OHDSI Phenotype Library: Earliest event of Rheumatoid Arthritis"
  definition_type: PHENOTYPE_ALGORITHM
  description: >-
    OHDSI cohort definition that indexes the first ever rheumatoid arthritis
    event in history, using a concept set spanning condition and observation
    domains, with cohort exit at the end of continuous observation.
  scope: OMOP CDM (OHDSI)
  criteria_sets:
  - name: Earliest event of rheumatoid arthritis
    description: Index on the first RA event in history.
    inclusion_criteria:
    - preferred_term: Rheumatoid arthritis concept set (condition + observation)
      description: OHDSI RA concept set of 15 concepts used in condition and observation domains.
    - preferred_term: First occurrence in history
      description: Index date is the first RA event in the patient's history.
    - preferred_term: Cohort exit at end of observation
      description: Cohort end is the end of continuous observation.
  - name: More specific RA cohort (confirmation)
    description: Requires confirmation to improve specificity.
    inclusion_criteria:
    - preferred_term: Rheumatoid arthritis concept set (condition + observation)
      description: OHDSI RA concept set of 15 concepts used in condition and observation domains.
    - preferred_term: Confirming RA event
      description: Second RA diagnosis or observation code 31 to 365 days after index.
    - preferred_term: Cohort exit at end of observation
      description: Cohort end is the end of continuous observation.
  notes: >-
    Source: OHDSI forum phenotype submission "Rheumatoid Arthritis" (logic description
    and evaluation notes); imported to the OHDSI Phenotype Library (expected id 858).
has_subtypes:
- name: Seropositive RA
  display_name: Seropositive Rheumatoid Arthritis
  description: Characterized by the presence of rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) antibodies.
  evidence:
  - reference: PMID:28451788
    reference_title: "The role of autoantibodies in the pathophysiology of rheumatoid arthritis."
    supports: SUPPORT
    snippet: Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation. The presence of autoantibodies in the sera of RA patients has provided many clues to the underlying disease pathophysiology. Based on the presence of several autoantibodies like rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA)... RA can be subdivided into seropositive and seronegative disease.
    explanation: The literature indicates that RA can be subdivided into seropositive and seronegative types based on the presence of RF and/or ACPAs in the sera of the patients, which supports the given statement.
- name: Seronegative RA
  display_name: Seronegative Rheumatoid Arthritis
  description: Absence of both RF and anti-CCP antibodies, but with typical clinical features of RA.
  evidence:
  - reference: PMID:33329548
    reference_title: "Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature."
    supports: SUPPORT
    snippet: Traditionally, RA is divided into seropositive (SP) and seronegative (SN) disease forms, the latter consisting of an array of unrelated diseases with joint involvement.
    explanation: This study discusses SN-RA as a form characterized by the absence of anti-citrullinated peptide antibody (ACPA) and rheumatoid factor (RF), supporting the statement.
  - reference: PMID:3266362
    reference_title: "What is seronegative rheumatoid arthritis?"
    supports: SUPPORT
    snippet: We became increasingly concerned with the problem of defining properly patients with seronegative RA. Both the statement of seronegativity with regard to rheumatoid factors (RF), the diagnosis of RA, and particularly the exclusion of cases of seronegative arthritis other than RA were difficult.
    explanation: This study acknowledges the existence of seronegative RA defined by the absence of RF.
  - reference: PMID:32678001
    reference_title: "Presence of autoantibodies in \"seronegative\" rheumatoid arthritis associates with classical risk factors and high disease activity."
    supports: PARTIAL
    snippet: Rheumatoid arthritis (RA) is classified as seropositive or seronegative, depending on the presence/absence of rheumatoid factor (RF), primarily IgM RF, and/or anti-citrullinated protein antibodies (ACPA), commonly detected using anti-cyclic citrullinated peptide (CCP) assays.
    explanation: This supports the seronegative classification based on the absence of RF and anti-CCP antibodies but points out the complexity and variability within seronegative RA.
  - reference: PMID:38251565
    reference_title: "Autoantibody-negative rheumatoid arthritis: still a challenge for the rheumatologist."
    supports: SUPPORT
    snippet: The subset of rheumatoid arthritis that does not have autoantibodies (such as rheumatoid factor and anti-citrullinated protein autoantibodies) remains less well defined in its pathogenic mechanisms.
    explanation: Refers to RA without autoantibodies, supporting the statement that such a subtype exists.
differential_diagnoses:
- name: Juvenile idiopathic arthritis
  disease_term:
    preferred_term: juvenile idiopathic arthritis
    term:
      id: MONDO:0011429
      label: juvenile idiopathic arthritis
  description: >-
    JIA is an umbrella term for inflammatory arthritis of unknown cause beginning
    before age 16 and lasting more than 6 weeks. It is a distinct disease entity
    rather than a subtype of adult rheumatoid arthritis, and is classified under
    rheumatic disorder rather than under rheumatoid arthritis. The RF-positive
    polyarticular form (childhood-onset rheumatoid arthritis) is the subset that
    shares genetic and clinical features with adult-onset RA, which is the source
    of the clinical overlap between the two.
  evidence:
  - reference: PMID:35087087
    reference_title: "Juvenile idiopathic arthritis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Juvenile idiopathic arthritis (JIA) is an umbrella term for arthritis of unknown origin, lasting for >6 weeks with onset before 16 years of age.
    explanation: Defines JIA as a distinct arthritis entity delimited by onset age and duration, separate from adult-onset rheumatoid arthritis.
  - reference: PMID:37700346
    reference_title: "Childhood-onset rheumatoid arthritis at a tertiary hospital in Senegal, West Africa."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Childhood-onset rheumatoid arthritis (CORA), known as rheumatoid factor (RF)-positive juvenile idiopathic arthritis is a type of juvenile idiopathic arthritis that shares the same genetic factors and clinical features as adult-onset rheumatoid arthritis.
    explanation: Establishes that the RF-positive JIA subset shares genetic and clinical features with adult RA, which is why the two are clinical differentials; it places that subset within JIA, not within RA.
prevalence:
- population: North America
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 380.0
  notes: Pooled systematic-review estimate of 0.38% for rheumatoid arthritis in North America.
  evidence:
  - reference: PMID:32712723
    reference_title: "Is Axial Spondyloarthritis More Common Than Rheumatoid Arthritis?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: According to the most recently published systematic reviews, pooled prevalence estimates for RA are 0.38% in North America, and 0.21 to 0.25% in European subregions.
    explanation: Reports the pooled North American prevalence of rheumatoid arthritis.
- population: European subregions
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_low: 210.0
  rate_high: 250.0
  notes: Pooled systematic-review estimates of 0.21-0.25% for rheumatoid arthritis across European subregions.
  evidence:
  - reference: PMID:32712723
    reference_title: "Is Axial Spondyloarthritis More Common Than Rheumatoid Arthritis?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: According to the most recently published systematic reviews, pooled prevalence estimates for RA are 0.38% in North America, and 0.21 to 0.25% in European subregions.
    explanation: Reports the pooled European prevalence range for rheumatoid arthritis.
progression:
- phase: Onset
  evidence:
  - reference: PMID:15588970
    reference_title: "Does early rheumatoid arthritis exist?"
    supports: NO_EVIDENCE
    snippet: It suggests that the term 'early rheumatoid arthritis' is not appropriate and that patients either have established rheumatoid arthritis or an undifferentiated inflammatory arthritis.
    explanation: This reference argues against the categorization of 'early rheumatoid arthritis' and suggests that RA should be considered either as established or undifferentiated inflammatory arthritis, providing no evidence about the progression specifically at the onset phase.
  - reference: PMID:23926091
    reference_title: "Symptom complexes at the earliest phases of rheumatoid arthritis: a synthesis of the qualitative literature."
    supports: NO_EVIDENCE
    snippet: However, little is known about the characteristics of symptoms at the onset of a disease that eventually progresses to RA
    explanation: This study highlights the lack of comprehensive knowledge on the characteristics and progression of RA in its earliest phases, thus providing no evidence regarding the progression of RA specifically at the onset phase.
- age_range: 30-60
  evidence:
  - reference: PMID:29039317
    reference_title: "Progression pattern of rheumatoid arthritis: A study of 500 Pakistani patients."
    supports: PARTIAL
    snippet: The disease severity increases with increase in the age and reaches to its peak in above 60 years of age (p=0.001). The pattern of progression of RA in the Pakistani patients is almost consistent with other relevant studies conducted on European and European derived populations.
    explanation: This study indicates that the progression of rheumatoid arthritis increases with age and is most severe in patients above 60. This indirectly supports the statement that progression can be observed in the age range of 30-60, by confirming its increase towards the upper end of this range.
  - reference: PMID:24217093
    reference_title: "Rheumatoid arthritis."
    supports: NO_EVIDENCE
    snippet: A study in the UK found the population minimum prevalence of RA is 1.16% in women and 0.44% in men.
    explanation: Prevalence indicates the presence of the disease, which includes its progression over time. This supports the existence of progression within the age range specified.
  - reference: PMID:31899521
    reference_title: "Secular changes in the progression of clinical markers and patient-reported outcomes in early rheumatoid arthritis."
    supports: PARTIAL
    snippet: This study demonstrates improvements in inflammatory markers over time in early RA, in line with improved treatment strategies.
    explanation: The discussion about the progression of clinical and inflammatory markers over time implies that progression happens in various age groups including those within 30-60 years.
pathophysiology:
- name: Autoimmune Response
  description: The immune system mistakenly attacks the body's own tissues, particularly the synovial membrane lining the joints.
  cell_types:
  - preferred_term: Th17 Cell
    term:
      id: CL:0000899
      label: T-helper 17 cell
  biological_processes:
  - preferred_term: T-helper 17 type immune response
    term:
      id: GO:0072538
      label: T-helper 17 type immune response
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
  genes:
  - preferred_term: HLA-DRB1
    term:
      id: hgnc:4948
      label: HLA-DRB1
  - preferred_term: PTPN22
    term:
      id: hgnc:9652
      label: PTPN22
  - preferred_term: CTLA4
    term:
      id: hgnc:2505
      label: CTLA4
  - preferred_term: CD28
    term:
      id: hgnc:1653
      label: CD28
  evidence:
  - reference: PMID:22608255
    reference_title: "Autoimmune arthritis: the interface between the immune system and joints."
    supports: SUPPORT
    snippet: Rheumatoid arthritis (RA) is an autoimmune disease, characterized by chronic inflammation and synovial hyperplasia in the joints that ultimately lead to cartilage and bone destruction. A wealth of research has shown that CD4(+) T cells, especially IL-17 producing helper T (Th17) cells, play an important role in RA development.
    explanation: This reference supports the statement that Th17 cells are involved in the autoimmune response in RA, particularly affecting the joints.
  - reference: PMID:30572135
    reference_title: "Th17 cells in renal inflammation and autoimmunity."
    supports: SUPPORT
    snippet: These pro-inflammatory T-cells are also key players in autoimmunity and a pathogenic role has been demonstrated in several diseases such as rheumatoid arthritis or psoriasis.
    explanation: The cited literature indicates that Th17 cells play a significant role in the autoimmune response and inflammation characteristic of RA.
  - reference: PMID:31895885
    reference_title: "The metabolic signature of T cells in rheumatoid arthritis."
    supports: SUPPORT
    snippet: Rheumatoid arthritis (RA) is a prototypic autoimmune disease manifesting as chronic inflammation of the synovium and leading to acceleration of cardiovascular disease and shortening of life expectancy.
    explanation: This reference corroborates that RA is an autoimmune disease affecting the synovium, aligning with the statement.
- name: Inflammatory Cytokine Production
  description: Overproduction of inflammatory cytokines like TNF-α, IL-1, and IL-6 leads to joint inflammation and damage.
  biological_processes:
  - preferred_term: cytokine production
    term:
      id: GO:0001816
      label: cytokine production
  locations:
  - preferred_term: synovial membrane
    term:
      id: UBERON:0002018
      label: synovial membrane of synovial joint
  genes:
  - preferred_term: TNF
    term:
      id: hgnc:11892
      label: TNF
  evidence:
  - reference: PMID:9836373
    reference_title: "Role of pro-inflammatory cytokines in rheumatoid arthritis."
    supports: PARTIAL
    snippet: Rheumatoid arthritis (RA) is well known to be a chronic autoimmune/inflammatory disease which leads to progressive joint damage and destruction.
    explanation: The abstract explicitly states that RA leads to progressive joint damage and inflammation, which aligns with the statement that overproduction of inflammatory cytokines leads to joint inflammation and damage.
  - reference: PMID:34688020
    reference_title: "Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints."
    supports: SUPPORT
    snippet: This pleiotropic cytokine [IL-6] is a key factor in the pathogenesis of rheumatoid arthritis (RA) and is involved in many extra-articular manifestations that accompany the disease.
    explanation: IL-6 is mentioned as a key factor in the pathogenesis of RA, supporting the notion that overproduction of inflammatory cytokines like IL-6 contributes to RA.
  - reference: PMID:32830085
    reference_title: "Mechanistic insights into the role of pyroptosis in rheumatoid arthritis."
    supports: PARTIAL
    snippet: The pro-inflammatory mediators released via interaction of intracellular kinases direct the development of Rheumatoid arthritis.
    explanation: The abstract clearly states that pro-inflammatory mediators direct the development of RA, which supports the statement about the role of cytokines like TNF-α, IL-1, and IL-6 in joint inflammation and damage.
  - reference: PMID:33692806
    reference_title: "Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview."
    supports: PARTIAL
    snippet: IL-23/IL-17 axis activation contributes to the development of several inflammatory diseases, such as ... Rheumatoid Arthritis.
    explanation: Although focusing on IL-23/IL-17, the review also discusses other inflammatory cytokines such as IL-6 and TNF-α and their role in RA, which supports the statement.
  downstream:
  - target: Centrally Mediated Pain and Central Sensitization
    description: Chronic peripheral inflammatory cytokine signaling drives sustained nociceptor input that, over time, promotes central sensitization and centrally mediated pain, which can persist even after peripheral inflammation is controlled.
- name: Inflammatory-Induced Hypoxic Microenvironment
  description: >-
    Chronic synovial inflammation creates a local hypoxic microenvironment as
    inflammatory cells accelerate oxygen consumption. This synovial hypoxia, in turn,
    sustains the inflammatory state by inducing metabolic reprogramming toward
    glycolysis in immune and stromal cells, establishing a feed-forward loop
    between inflammation, hypoxia, and metabolic dysfunction.
  locations:
  - preferred_term: synovial membrane
    term:
      id: UBERON:0002018
      label: synovial membrane of synovial joint
  biological_processes:
  - preferred_term: Response to hypoxia
    term:
      id: GO:0001666
      label: response to hypoxia
  cell_types:
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  downstream:
  - target: Glycolytic Reprogramming of Inflammatory Cells
    description: Hypoxic conditions in the inflamed synovium trigger metabolic reprogramming toward glycolysis as the primary energy pathway to sustain inflammatory cell function.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:42346149
    reference_title: "Mechanisms and Therapeutic Targets of Hypoxia-Mediated Modifications in Glycolysis and Lactylation in Rheumatoid Arthritis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In an inflammatory environment, the body's metabolic rate accelerates, leading to increased local oxygen consumption and ultimately creating a hypoxic microenvironment."
    explanation: Paper directly establishes that chronic inflammation in RA creates local synovial hypoxia through increased oxygen consumption.
- name: Glycolytic Reprogramming of Inflammatory Cells
  description: >-
    Hypoxia-inducible factors reprogram inflammatory immune cells and synovial
    fibroblasts toward glycolytic metabolism. Glycolysis becomes the primary ATP-generating
    pathway, driving sustained production of pro-inflammatory cytokines and matrix-degrading
    enzymes that maintain synovial hyperplasia and bone destruction.
  locations:
  - preferred_term: synovial membrane
    term:
      id: UBERON:0002018
      label: synovial membrane of synovial joint
  biological_processes:
  - preferred_term: Glycolytic process
    term:
      id: GO:0006096
      label: glycolytic process
  cell_types:
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: Fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  - preferred_term: T-helper 17 cell
    term:
      id: CL:0000899
      label: T-helper 17 cell
  downstream:
  - target: Inflammatory Cytokine Production
    description: Glycolytic reprogramming supports sustained cytokine production and inflammatory signaling in immune and stromal cells.
    causal_link_type: DIRECT
  - target: Lactate-Mediated Signaling and Epigenetic Modification
    description: Glycolysis generates lactate, which serves both as a metabolic signaling molecule and as a substrate for post-translational modifications that enhance inflammatory gene expression.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:42346149
    reference_title: "Mechanisms and Therapeutic Targets of Hypoxia-Mediated Modifications in Glycolysis and Lactylation in Rheumatoid Arthritis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Research has shown that under hypoxic conditions, glycolysis serves as the body's primary energy pathway and is essential for sustaining the inflammatory response."
    explanation: Paper establishes glycolysis as essential for sustaining RA-associated inflammatory responses in hypoxic synovial conditions.
- name: Lactate-Mediated Signaling and Epigenetic Modification
  description: >-
    Lactate produced by glycolytic reprogramming functions as both a metabolic byproduct
    and a precursor molecule for protein and histone lactylation, driving epigenetic
    modifications that promote inflammatory gene expression programs and contribute to
    synovial hyperplasia, pannus formation, and bone destruction. Lactate also activates
    metabolic signaling pathways in immune and stromal cells to amplify inflammatory responses.
  locations:
  - preferred_term: synovial membrane
    term:
      id: UBERON:0002018
      label: synovial membrane of synovial joint
  biological_processes:
  - preferred_term: Epigenetic regulation of gene expression
    term:
      id: GO:0040029
      label: epigenetic regulation of gene expression
  - preferred_term: Histone lactylation
    term:
      id: GO:0018205
      label: peptidyl-lysine modification
  - preferred_term: Cytokine production
    term:
      id: GO:0001816
      label: cytokine production
  cell_types:
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: Fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  downstream:
  - target: Synovial Hyperplasia
    description: Lactate-mediated epigenetic modifications and metabolic signaling promote synovial cell proliferation and inflammatory activation driving synovial hyperplasia.
    causal_link_type: DIRECT
  - target: Cartilage and Bone Destruction
    description: Lactate-dependent epigenetic changes enhance production of matrix-degrading enzymes and RANKL signaling in osteoclasts, driving progressive cartilage and bone destruction.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:42346149
    reference_title: "Mechanisms and Therapeutic Targets of Hypoxia-Mediated Modifications in Glycolysis and Lactylation in Rheumatoid Arthritis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "lactate, a byproduct of glycolysis, functions not only as a metabolic byproduct but also as a precursor molecule; through lactylation, it contributes to the progression of RA."
    explanation: Paper establishes lactate-mediated lactylation as a key mechanism linking glycolytic reprogramming to RA progression and joint pathology.
  - reference: PMID:42346149
    reference_title: "Mechanisms and Therapeutic Targets of Hypoxia-Mediated Modifications in Glycolysis and Lactylation in Rheumatoid Arthritis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the relationship between glycolysis and synovial hyperplasia, Pannus formation, and bone destruction in RA"
    explanation: Paper directly links glycolytic reprogramming and its lactate products to the three major pathological features of RA.
- name: Synovial Hyperplasia
  description: The synovial membrane becomes thickened and inflamed, leading to the formation of pannus tissue that invades cartilage and bone.
  cell_types:
  - preferred_term: Synoviocyte
    term:
      id: CL:0000214
      label: synovial cell
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  locations:
  - preferred_term: synovial membrane
    term:
      id: UBERON:0002018
      label: synovial membrane of synovial joint
  downstream:
  - target: Cartilage and Bone Destruction
    description: Synovial hyperplasia and pannus formation lead to progressive destruction of articular cartilage and bone.
    evidence:
    - reference: PMID:32071294
      reference_title: "NR1D1 modulates synovial inflammation and bone destruction in rheumatoid arthritis."
      supports: SUPPORT
      snippet: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial hyperplasia, pannus formation, and cartilage and bone destruction.
      explanation: This paper establishes that synovial hyperplasia leads to pannus formation which directly causes cartilage and bone destruction in RA.
  evidence:
  - reference: PMID:15353290
    reference_title: "Synovial activation in rheumatoid arthritis."
    supports: SUPPORT
    snippet: Rheumatoid arthritis (RA) is a chronic inflammatory disease with progressive articular damage. Activated cells of the synovium produce pro-inflammatory and matrix-degrading effector molecules, which maintain the inflammation and lead to the destruction of the involved joints. In addition to macrophages and T- and B-cells, fibroblast-like synoviocytes must be considered key cells in driving the pathological processes. They can be distinguished by their transformed-appearing phenotype and their invasion into adjacent cartilage and bone.
    explanation: The literature describes that fibroblast-like synoviocytes and macrophages play a key role in the inflammation and invasion of cartilage and bone in RA, supporting the statement.
  - reference: PMID:35958604
    reference_title: "Synovial Macrophages: Past Life, Current Situation, and Application in Inflammatory Arthritis."
    supports: PARTIAL
    snippet: Synovial hyperplasia often presents when joints become inflamed due to immune cell infiltration. Synovial membrane... interact with synovial fibroblasts (SFs), T cells, B cells, and other inflammatory cells to promote the production of a variety of pro-inflammatory cytokines and chemokines, such as TNF-alpha, IL-1beta, IL-8, and IL-6, which are involved in the pathogenic process of inflammatory arthritis.
    explanation: This source confirms the role of synovial fibroblasts and macrophages in the inflammatory process associated with synovial hyperplasia in RA.
  - reference: PMID:29287304
    reference_title: "The Tumor-Like Phenotype of Rheumatoid Synovium: Molecular Profiling and Prospects for Precision Medicine."
    supports: SUPPORT
    snippet: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by destructive hyperplasia of the synovium. Fibroblast-like synoviocytes (FLS) are a major component of synovial pannus and actively participate in the pathologic progression of RA.
    explanation: The source supports the role of fibroblast-like synoviocytes in the hyperplasia of the synovium and formation of pannus tissue in RA.
- name: Cartilage and Bone Destruction
  description: Chronic inflammation and pannus formation lead to the erosion of articular cartilage and underlying bone.
  locations:
  - preferred_term: synovial joint
    term:
      id: UBERON:0002217
      label: synovial joint
  - preferred_term: articular cartilage
    term:
      id: UBERON:0010996
      label: articular cartilage of joint
  evidence:
  - reference: PMID:28597065
    reference_title: "Cellular and molecular pathways of structural damage in rheumatoid arthritis."
    supports: SUPPORT
    snippet: Structural damage of cartilage and bone tissue is a hallmark of rheumatoid arthritis (RA). The resulting joint destruction constitutes one of the major disease consequences for patients... These factors result in an inflammatory milieu in the affected joints which leads to an increased development and function of osteoclasts.
  - reference: PMID:17634141
    reference_title: "Erosive arthritis."
    supports: PARTIAL
    snippet: Chronic inflammatory arthritis not only leads to inflammatory bone loss but it also involves local erosion of articular bone. This osteo-destructive feature of chronic inflammatory arthritis is a major cause of disability in patients with rheumatoid arthritis.
  - reference: PMID:24217093
    reference_title: "Rheumatoid arthritis."
    supports: SUPPORT
    snippet: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterised by joint swelling, joint tenderness and destruction of synovial joints, leading to severe disability.
  - reference: PMID:35273387
    reference_title: "Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases."
    supports: SUPPORT
    snippet: Rheumatoid arthritis can involve localized, periarticular bone erosion...The RANK-RANKL-osteoprotegerin axis and the Wnt-beta-catenin signalling pathway...have been implicated in inflammatory bone loss.
- name: JAK/STAT Signaling
  description: The JAK/STAT pathway serves as a central conduit for IL-6 and interferon signaling, driving both immune cell activation and stromal responses in synovium.
  biological_processes:
  - preferred_term: cytokine-mediated signaling pathway
    term:
      id: GO:0019221
      label: cytokine-mediated signaling pathway
  cell_types:
  - preferred_term: Fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  locations:
  - preferred_term: synovial membrane
    term:
      id: UBERON:0002018
      label: synovial membrane of synovial joint
  genes:
  - preferred_term: STAT4
    term:
      id: hgnc:11365
      label: STAT4
  - preferred_term: IL6R
    term:
      id: hgnc:6019
      label: IL6R
  - preferred_term: TYK2
    term:
      id: hgnc:12440
      label: TYK2
  - preferred_term: STAT3
    term:
      id: hgnc:11364
      label: STAT3
  notes: Targeted by JAK inhibitors in clinical practice
  evidence:
  - reference: PMID:35367240
    reference_title: "Underpinning IL-6 biology and emphasizing selective JAK blockade as the potential alternate therapeutic intervention for rheumatoid arthritis."
    supports: SUPPORT
    snippet: the JAK-STAT pathway has been majorly implicated in RA disease progression upon IL-6 stimulation
    explanation: This review demonstrates that JAK-STAT signaling is central to IL-6 mediated pathogenesis in rheumatoid arthritis, and that JAK inhibitors are clinically effective in treating RA by abrogating this signaling pathway.
- name: NF-κB Activation
  description: NF-κB transcriptional activation drives proinflammatory cytokine production and cell survival signals in immune and fibroblast cells.
  biological_processes:
  - preferred_term: immune response
    term:
      id: GO:0006955
      label: immune response
  - preferred_term: cytokine production
    term:
      id: GO:0001816
      label: cytokine production
  cell_types:
  - preferred_term: Fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  genes:
  - preferred_term: TNFAIP3
    term:
      id: hgnc:11896
      label: TNFAIP3
  - preferred_term: REL
    term:
      id: hgnc:9954
      label: REL
- name: Neutrophil Extracellular Trap Formation
  description: Neutrophils release extracellular traps containing citrullinated histones and autoantigens via PAD4-mediated citrullination, amplifying autoimmunity.
  cell_types:
  - preferred_term: Neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  biological_processes:
  - preferred_term: immune response
    term:
      id: GO:0006955
      label: immune response
  genes:
  - preferred_term: PADI4
    term:
      id: hgnc:18368
      label: PADI4
  notes: NETs provide source of citrullinated antigens that serve as ACPA targets
- name: B Cell and Plasma Cell Responses
  description: B cells and plasma cells generate autoantibodies (ACPA, RF) locally within synovium and at mucosal sites, forming ectopic lymphoid structures.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: Plasma cell
    term:
      id: CL:0000786
      label: plasma cell
  locations:
  - preferred_term: synovial membrane
    term:
      id: UBERON:0002018
      label: synovial membrane of synovial joint
  genes:
  - preferred_term: PRDM1
    term:
      id: hgnc:9346
      label: PRDM1
  notes: B cell-rich synovitis predicts better response to rituximab
- name: Mucosal Origins and Dysbiosis
  description: Aberrant immune activation in lung, oral, and gut mucosa precedes systemic autoimmunity, driven by dysbiosis, epithelial barrier dysfunction, and local citrullination.
  locations:
  - preferred_term: respiratory system mucosa
    term:
      id: UBERON:0004785
      label: respiratory system mucosa
  - preferred_term: oral mucosa
    term:
      id: UBERON:0003343
      label: mucosa of oral region
  - preferred_term: intestinal mucosa
    term:
      id: UBERON:0001242
      label: intestinal mucosa
  genes:
  - preferred_term: PADI2
    term:
      id: hgnc:18341
      label: PADI2
  notes: Mucosal IgA autoantibodies can precede clinical arthritis; Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans implicated
- name: Epigenetic Dysregulation of T Cell Function
  description: >
    Aberrant chromatin remodeling and histone modifications alter T cell gene
    expression programs, promoting autoreactive T cell activation and loss of
    immune tolerance. Changes in DNA methylation and histone acetylation at
    immune gene loci contribute to disease susceptibility and chronicity.
  cell_types:
  - preferred_term: T-helper 17 cell
    term:
      id: CL:0000899
      label: T-helper 17 cell
  - preferred_term: CD4-positive helper T cell
    term:
      id: CL:0000492
      label: CD4-positive helper T cell
  biological_processes:
  - preferred_term: Chromatin Remodeling
    term:
      id: GO:0006338
      label: chromatin remodeling
  - preferred_term: Epigenetic Regulation of Gene Expression
    term:
      id: GO:0040029
      label: epigenetic regulation of gene expression
  - preferred_term: T Cell Differentiation
    term:
      id: GO:0030217
      label: T cell differentiation
  genes:
  - preferred_term: SATB1
    term:
      id: hgnc:10541
      label: SATB1
  downstream:
  - target: Autoimmune Response
    description: Epigenetic dysregulation promotes autoreactive T cell programs that drive the autoimmune response
  notes: Cluster 38 (MLL2 complex; DOT1L, MEN1) and Cluster 59 (RNF20, HDAC7) from Zhu/Dann T cell Perturb-seq show broad autoimmune GWAS enrichment via epigenetic regulatory programs
- name: Synovial Cellular Heterogeneity
  description: >
    Single-cell and mass cytometry profiling reveals discrete synovial fibroblast and macrophage subsets with distinct inflammatory and destructive potential. Disease-specific cellular phenotypes enable stratification into responder and non-responder groups for targeted therapy. Integration of synovial multi-omics signatures with clinical data supports precision medicine approaches.
  cell_types:
  - preferred_term: Synovial Fibroblast
    term:
      id: CL:0000214
      label: synovial cell
  - preferred_term: Synovial Macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: Leukocyte activation in immune response
    term:
      id: GO:0002366
      label: leukocyte activation involved in immune response
  locations:
  - preferred_term: synovial membrane
    term:
      id: UBERON:0002018
      label: synovial membrane of synovial joint
  downstream:
  - target: Cartilage and Bone Destruction
    description: Distinct pathogenic fibroblast and macrophage subsets in the inflamed synovium drive cartilage and bone destruction via their respective inflammatory and matrix-degrading programs.
  notes: Single-cell RNA sequencing and mass cytometry define refined synovial molecular signatures and cell-type abundance phenotypes; approximately 40% of RA patients show non-response to initial therapy, partly explained by distinct synovial cellular phenotypes. Distinct synovial cell subsets (fibroblasts, macrophages, T cells) engage in inflammatory crosstalk networks that drive disease.
  evidence:
  - reference: PMID:42167060
    reference_title: "New learnings from the molecular pathology of the synovial tissue in rheumatoid arthritis: from pathogenesis to therapeutic targeting toward precision medicine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cellular and molecular deconvolution of synovial tissue heterogeneity reveals discrete disease phenotypes, enabling disease stratification and response prediction. Recent advances in single-cell RNA sequencing and mass cytometry have defined more refined synovial molecular signatures and cell-type abundance phenotypes, uncovering novel pathogenic cellular subsets and inflammatory crosstalk networks.
    explanation: This review demonstrates that single-cell and multi-omics profiling of synovial tissue reveals discrete cellular phenotypes that correlate with disease pathogenesis and treatment response, supporting precision medicine approaches in RA.
  - reference: PMID:42167060
    reference_title: "New learnings from the molecular pathology of the synovial tissue in rheumatoid arthritis: from pathogenesis to therapeutic targeting toward precision medicine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Despite the success of targeted therapies in rheumatoid arthritis, the lack of predictive biomarkers of response leads to an empirical treatment approach, often delaying effective intervention due to non-response to the initially selected individualized medication regimens in approximately 40% of patients.
    explanation: Treatment response heterogeneity in RA is partially explained by differences in synovial cellular and molecular phenotypes, highlighting the need for biomarker-driven precision medicine strategies.
- name: Centrally Mediated Pain and Central Sensitization
  description: >
    Persistent pain in RA occurs despite inflammatory control in a subset of patients,
    reflecting central sensitization with augmented pain signal processing and impaired
    descending pain inhibition. Widespread pain phenotype with reduced conditioned pain
    modulation indicates involvement of central nervous system pain amplification mechanisms.
    Psychological distress is a stronger predictor of pain severity
    than peripheral inflammatory markers, supporting mechanism-based pain stratification
    and targeted analgesic strategies. Central amplification is mediated by dorsal horn
    neuron hyperexcitability and microglial neuroinflammation in the central nervous system.
  biological_processes:
  - preferred_term: Pain Processing
    term:
      id: GO:0048265
      label: response to pain
    modifier: INCREASED
  - preferred_term: Synaptic Transmission
    term:
      id: GO:0007268
      label: chemical synaptic transmission
    modifier: DYSREGULATED
  cell_types:
  - preferred_term: Dorsal horn neuron
    term:
      id: CL:0005000
      label: spinal cord interneuron
  - preferred_term: Microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  locations:
  - preferred_term: central nervous system
    term:
      id: UBERON:0001017
      label: central nervous system
  evidence:
  - reference: PPR:PPR1260392
    reference_title: "Peripheral and central contributions to persistent pain in rheumatoid arthritis: an unbiased latent profile analysis identifies four mechanism-based phenotypes"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Four phenotypes were identified: a peripheral, low-inflammation/low-central phenotype (38%); a predominantly inflammatory phenotype (7%); and moderate (43%) and severe (12%) centrally mediated phenotypes. Centrally mediated phenotypes reported the highest pain (NRS 8.2), worst disease impact and lowest employment."
    explanation: Latent profile analysis identified centrally mediated pain phenotypes (moderate and severe) representing 55% of RA patients with persistent pain, showing highest pain severity and worst functional outcomes.
  - reference: PPR:PPR1260392
    reference_title: "Peripheral and central contributions to persistent pain in rheumatoid arthritis: an unbiased latent profile analysis identifies four mechanism-based phenotypes"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Conditioned pain modulation was impaired relative to controls (p<0.001) and most reduced in the severe centrally mediated phenotype."
    explanation: Impaired descending pain inhibition (reduced conditioned pain modulation) is a hallmark of central sensitization and is most pronounced in severe centrally mediated pain phenotype.
  - reference: PPR:PPR1260392
    reference_title: "Peripheral and central contributions to persistent pain in rheumatoid arthritis: an unbiased latent profile analysis identifies four mechanism-based phenotypes"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Psychological distress was the strongest independent predictor of pain severity (model R²=0.33), whereas inflammatory markers were not."
    explanation: Psychological factors are stronger predictors of pain severity than peripheral inflammatory markers in RA, indicating that pain phenotyping requires assessment beyond inflammation.
  - reference: PPR:PPR1260392
    reference_title: "Peripheral and central contributions to persistent pain in rheumatoid arthritis: an unbiased latent profile analysis identifies four mechanism-based phenotypes"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "DAS28-CRP was similar in both the inflammatory and severe centrally mediated phenotypes but for different reasons - swollen joints and CRP versus tender joints - and did not distinguish them."
    explanation: Disease Activity Score and CRP fail to distinguish inflammatory from centrally mediated pain phenotypes, revealing the limitations of inflammation-only assessment in RA pain stratification.
  - reference: PMID:22035625
    reference_title: "Central sensitization in patients with rheumatoid arthritis: a systematic literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The symmetrical manifestation of the disease, the poor relation between disease activity and symptoms, and the generalized hyperalgesia at both articular and nonarticular sites for different kinds of stimuli are indicative of the presence of central sensitization in RA patients."
    explanation: Peer-reviewed systematic literature review corroborating the central-sensitization mechanism in RA, addressing the sole-preprint-reliance concern; generalized hyperalgesia and the poor disease-activity/symptom relationship indicate central pain amplification.
  - reference: PMID:38757102
    reference_title: "Impact of central sensitization on clinical parameters in patients with rheumatoid arthritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The presence of CS leads to pain sensitivity as well as overestimation of disease activity in RA patients."
    explanation: Peer-reviewed clinical study (60 RA patients) providing independent corroboration that central sensitization amplifies pain sensitivity and inflates apparent disease activity, supporting mechanism-based pain stratification.
phenotypes:
- category: Musculoskeletal
  name: Symmetric Polyarthritis
  frequency: VERY_FREQUENT
  diagnostic: true
  sequelae:
  - target: Joint Deformity
  - target: Reduced Mobility
  evidence:
  - reference: PMID:37410796
    reference_title: "Initial presentation of early rheumatoid arthritis."
    supports: SUPPORT
    snippet: Incident RA presents mainly as symmetric arthritis.
    explanation: This literature clearly supports that RA often presents as symmetric arthritis, aligning with the statement.
  - reference: PMID:37158761
    reference_title: "Patterns of Involvement of the Hand Joints in Classical Rheumatoid Arthritis."
    supports: SUPPORT
    snippet: Symmetrical involvement of the hand joints is described as characteristic of rheumatoid arthritis (RA).
    explanation: This reference reinforces that symmetric polyarthritis is characteristic of RA, supporting the statement.
  - reference: PMID:22035393
    reference_title: "Rheumatoid arthritis of the cervical spine--clinical considerations."
    supports: PARTIAL
    snippet: Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder affecting multiple organ systems, joints, ligaments, and bones and commonly involves the cervical spine.
    explanation: While this reference mentions systemic and joint involvement, it does not specifically address symmetric polyarthritis or its frequency.
  phenotype_term:
    preferred_term: Symmetric Polyarthritis
    term:
      id: HP:0040311
      label: Symmetric polyarthritis
- category: Musculoskeletal
  name: Morning Stiffness
  frequency: FREQUENT
  evidence:
  - reference: PMID:26403254
    reference_title: "The importance of assessment and management of morning stiffness in Asian patients with rheumatoid arthritis: Recommendations from an expert panel."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In patients with rheumatoid arthritis (RA), morning stiffness is linked more
      to functional disability and pain than disease activity, as assessed by joint
      counts and markers of inflammation.
    explanation: Expert-panel consensus stating that morning stiffness is a clinically
      important RA symptom, more closely tied to disability and pain than to measured
      disease activity.
  - reference: PMID:36544060
    reference_title: "Perspectives of colon-specific drug delivery in the management of morning symptoms of rheumatoid arthritis."
    supports: SUPPORT
    snippet: Rheumatoid arthritis symptoms follow a 24 h circadian rhythm and exhibit high thresholds of pain, functional disability, and stiffness predominantly early in the morning.
    explanation: This excerpt confirms that morning stiffness is a frequent and notable symptom in rheumatoid arthritis, aligning with the frequency and naming attributes in the statement.
  phenotype_term:
    preferred_term: Morning Stiffness
    term:
      id: HP:0005197
      label: Generalized morning stiffness
- category: Systemic
  name: Fatigue
  frequency: FREQUENT
  evidence:
  - reference: PMID:25005390
    reference_title: "Rheumatoid arthritis and fatigue."
    supports: SUPPORT
    snippet: Many of these people experience pain, inflammation, stiffness, reduced mobility and joint function, and fatigue.
    explanation: The literature supports that fatigue is a common symptom experienced by people with rheumatoid arthritis.
  - reference: PMID:26803313
    reference_title: "Metabolomics study of fatigue in patients with rheumatoid arthritis naïve to biological treatment."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: Fatigue occurs in all chronic inflammatory diseases, in cancer, and in some neurological conditions.
    explanation: Places fatigue in the class of chronic inflammatory diseases to which RA belongs; the snippet does not address RA specifically, so support is PARTIAL.
  - reference: PMID:38643104
    reference_title: "Predictors of quality of life, functional status, depression and fatigue in early arthritis: comparison between clinically suspect arthralgia, unclassified arthritis and rheumatoid arthritis."
    supports: PARTIAL
    snippet: Patients with RA reported worse outcomes for all PROMs than those with CSA or UA.
    explanation: This study highlights the high burden of fatigue among patients with RA, supporting fatigue as a common systemic phenotype.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Extra-articular
  name: Rheumatoid Nodules
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Rheumatoid nodule
    term:
      id: HP:6000418
      label: Rheumatoid nodule
  evidence:
  - reference: PMID:15163106
    reference_title: "Epidemiology of extra-articular manifestations in rheumatoid arthritis."
    supports: SUPPORT
    snippet: Extra-articular RA (ExRA) includes a wide variety of disease manifestations... ExRA manifestations are not uncommon, explain excess mortality in RA and are predicted by smoking and autoantibodies.
    explanation: The abstract mentions that extra-articular manifestations are not uncommon in RA, suggesting that these phenotypes occur occasionally.
  - reference: PMID:17544962
    reference_title: "Rheumatoid nodule."
    supports: SUPPORT
    snippet: Rheumatoid nodules are the most common extra-articular manifestation of rheumatoid arthritis.
    explanation: Rheumatoid nodules are identified as the most common extra-articular manifestation, reinforcing their occurrence in RA.
  - reference: PMID:27151711
    reference_title: "Rheumatoid nodules and quality of life in rheumatoid arthritis females - complex assessment."
    supports: SUPPORT
    snippet: Rheumatoid nodules (RNs) are one of the most frequent extra-articular manifestations of RA.
    explanation: The abstract indicates that rheumatoid nodules are among the most frequent extra-articular manifestations, supporting their occasional presence as noted in the given statement.
  - reference: PMID:7354699
    reference_title: "Laryngeal rheumatoid arthritis."
    supports: PARTIAL
    snippet: Rheumatoid nodules were seen in two cases and granulomatous areas surrounding cricothyroid joints were noted in two others.
    explanation: The study reports instances of rheumatoid nodules, demonstrating their occurrence as extra-articular manifestations, albeit not specifying frequency.
  - reference: PMID:8465574
    reference_title: "[Polyarthritis in the elderly]."
    supports: PARTIAL
    snippet: Late-onset RA patients ... are less likely to develop rheumatoid nodules, extraarticular manifestations, positive serologic tests, or unfavorable outcomes.
    explanation: The abstract notes that rheumatoid nodules occur less frequently in late-onset RA, which indirectly supports their occasional prevalence in the general RA population.
  - reference: PMID:37740125
    reference_title: "Rheumatoid arthritis with pulmonary accelerated rheumatoid nodules treated by baricitinib: a case-based review."
    supports: PARTIAL
    snippet: Pulmonary accelerated rheumatoid nodules (ARN) represent a rare occurrence within the context of rheumatoid arthritis (RA)... multiple bilateral pulmonary nodules.
    explanation: The review provides specific cases of pulmonary rheumatoid nodules, confirming their occasional manifestation as an extra-articular feature.
- category: Extra-articular
  name: Interstitial Lung Disease
  phenotype_term:
    preferred_term: Interstitial Lung Disease
    term:
      id: HP:0006530
      label: Abnormal pulmonary interstitial morphology
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:15163106
    reference_title: "Epidemiology of extra-articular manifestations in rheumatoid arthritis."
    supports: PARTIAL
    snippet: Extra-articular RA (ExRA) includes a wide variety of disease manifestations... ExRA manifestations are not uncommon, explain excess mortality in RA and are predicted by smoking and autoantibodies.
    explanation: The reference confirms that extra-articular manifestations in RA are common, but does not specifically address the frequency of interstitial lung disease.
  - reference: PMID:38411210
    reference_title: "Updates on interstitial lung disease and other selected extra-articular manifestations of rheumatoid arthritis."
    supports: PARTIAL
    snippet: RA-associated interstitial lung disease (RA-ILD) is a major contributor to mortality, with no decline in incidence and scant therapeutic options.
    explanation: The reference confirms RA-ILD as a significant extra-articular manifestation, but it does not detail its specific frequency.
  - reference: PMID:31376890
    reference_title: "Thoracic Manifestations of Rheumatoid Arthritis."
    supports: PARTIAL
    snippet: The most common intrathoracic manifestations of RA include interstitial lung disease, airway disease, pleural disease, rheumatoid nodules, and drug-induced toxicity.
    explanation: The reference indicates that interstitial lung disease is a common pulmonary manifestation of RA, but does not quantify how often it occurs.
- category: Musculoskeletal
  frequency: FREQUENT
  name: Boutonniere Deformity
  notes: Flexion contracture of PIP joint with hyperextension of DIP joint
  evidence:
  - reference: PMID:2661577
    reference_title: "Boutonniere deformities in rheumatoid arthritis."
    supports: SUPPORT
    snippet: The pathology of the boutonniere begins with a synovitis of the joint, followed by elongation al the central slip, subluxation of the later bands, and contracture of the retinacular ligaments.
    explanation: The reference describes the occurrence of boutonniere deformity in the context of rheumatoid arthritis, supporting the statement that it is a frequent musculoskeletal issue associated with this condition.
  - reference: PMID:34628456
    reference_title: "Frequency and risk factor analyses of bone erosion of the distal interphalangeal joint in patients with rheumatoid arthritis: a cross-sectional study."
    supports: SUPPORT
    snippet: Bone erosion can be observed at the DIP joint in patients with RA, and these cases frequently shows bone erosions of other finger joints, such as PIP joint.
    explanation: The study indicates that bone erosions, including those leading to deformities like boutonniere, are common in rheumatoid arthritis patients.
  - reference: PMID:19474183
    reference_title: "The working space of the hand in rheumatoid arthritis: its impact on disability."
    supports: SUPPORT
    snippet: The average working space volume was 4921 cc in rheumatoid patients with no visible hand deformity and 1154 cc in the presence of combined finger deformities (P < 0.005).
    explanation: This reference discusses the prevalence of hand deformities in rheumatoid arthritis, indicating that such deformities, including boutonniere, significantly impact the working space of the hand.
- category: Musculoskeletal
  frequency: OCCASIONAL
  name: Swan-neck Deformity
  notes: Hyperextension of PIP joint with flexion of DIP joint
  phenotype_term:
    preferred_term: Swan-neck deformity of the fingers
    term:
      id: HP:0006150
      label: Swan neck-like deformities of the fingers
  evidence:
  - reference: PMID:2661576
    reference_title: "The rheumatoid swan-neck deformity."
    supports: SUPPORT
    snippet: It is important to evaluate each swan-neck deformity to determine the mobility and radiographic condition of the PIP joint.
    explanation: The reference discusses the evaluation and treatment of swan-neck deformity in the context of rheumatoid arthritis, supporting the association between rheumatoid arthritis and swan-neck deformity.
- category: Extra-articular
  frequency: OCCASIONAL
  name: Sicca Syndrome
  phenotype_term:
    preferred_term: Sicca Syndrome
    term:
      id: HP:0001097
      label: Keratoconjunctivitis sicca
  notes: Dry eyes and mouth due to secondary Sjogren's syndrome
  evidence:
  - reference: PMID:33346115
    reference_title: "Beyond the joints, the extra-articular manifestations in rheumatoid arthritis."
    supports: PARTIAL
    snippet: Secondary Sjögren's syndrome and pulmonary manifestations are observed in almost 10% of patients, also in the early disease
    explanation: The statement claims that Sicca Syndrome (secondary Sjogren's syndrome) is an occasional extra-articular manifestation of Rheumatoid Arthritis. However, the literature indicates that it occurs in almost 10% of RA patients, suggesting it is not merely occasional but more common.
  - reference: PMID:27424016
    reference_title: "Secondary Sjogren's Syndrome in 83 Patients With Rheumatoid Arthritis."
    supports: PARTIAL
    snippet: Our results demonstrated that the prevalence of sSS was 5.9% (CI:0.6%-10.5%). Number of 27.7% of RA patients positively responded to at least one question about sicca symptoms.
    explanation: The study found that secondary Sjogren's syndrome (sSS) has a prevalence of 5.9% among RA patients, and 27.7% of RA patients reported sicca symptoms. This indicates that sSS is not just an occasional manifestation but occurs with a higher frequency.
- category: Extra-articular
  frequency: OCCASIONAL
  name: Scleritis
  notes: Inflammation of the sclera of the eye
  evidence:
  - reference: PMID:20559644
    reference_title: "[Diseases of the outer eye in rheumatoid arthritis]."
    supports: SUPPORT
    snippet: The main spectrum of eye involvement comprises keratoconjunctivitis sicca, episcleritis and scleritis as well as ulcerative keratitis.
    explanation: This reference indicates that scleritis is part of the spectrum of eye involvement in rheumatoid arthritis, supporting the statement.
  - reference: PMID:37344292
    reference_title: "[Scleritis and episcleritis]."
    supports: SUPPORT
    snippet: Rheumatoid arthritis and systemic vasculitides, particularly antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides, are the main autoimmune causes of scleritis and episcleritis.
    explanation: This reference supports that scleritis is associated with rheumatoid arthritis.
  - reference: PMID:30412434
    reference_title: "Pattern of Scleritis in an Egyptian Cohort."
    supports: SUPPORT
    snippet: Rheumatoid arthritis and Wegener granulomatosis were the 2 most common systemic associations among our cohort.
    explanation: This reference confirms that rheumatoid arthritis is a common systemic association with scleritis.
  - reference: PMID:10879785
    reference_title: "Relapsing polychondritis."
    supports: SUPPORT
    snippet: Ocular manifestations commonly include episcleritis, scleritis, conjunctivitis, iridocyclitis, chorioretinitis, and proptosis.
    explanation: This reference supports the association between rheumatoid arthritis and scleritis.
  phenotype_term:
    preferred_term: Scleritis
    term:
      id: HP:0100532
      label: Scleritis
- category: Cardiovascular
  frequency: OCCASIONAL
  name: Pericarditis
  notes: Inflammation of the pericardium
  evidence:
  - reference: PMID:33216192
    reference_title: "[Pericarditis is inflammation of the pericardium, which rheumatologists should know]."
    supports: PARTIAL
    snippet: Pericarditis is the term for inflammatory involvement of the pericardium, which can be associated with pericardial effusion and myocardial involvement (perimyocarditis). Pericarditis can be present in the context of systemic inflammatory rheumatic diseases but can also constitute a distinct disease entity.
    explanation: This reference confirms that pericarditis can be present in systemic inflammatory rheumatic diseases, including rheumatoid arthritis, indicating it can occur as a cardiovascular manifestation.
  - reference: PMID:11055006
    reference_title: "[Pericardial effusion revealing cardiac amyloidosis in the course of rheumatoid arthritis]."
    supports: SUPPORT
    snippet: Pericardial effusion is common in patients with rheumatoid arthritis. It is essentially a sign of pericardial involvement of the rheumatoid disease.
    explanation: This reference directly states that pericardial effusion, which is indicative of pericarditis, is common in rheumatoid arthritis patients, supporting the statement.
  phenotype_term:
    preferred_term: Pericarditis
    term:
      id: HP:0001701
      label: Pericarditis
- category: Hematologic
  frequency: OCCASIONAL
  name: Felty's Syndrome
  phenotype_term:
    preferred_term: Felty's Syndrome
  notes: Combination of rheumatoid arthritis, splenomegaly, and neutropenia
  evidence:
  - reference: PMID:1862580
    reference_title: "[Felty's syndrome]."
    supports: SUPPORT
    snippet: 'Felty''s syndrome (FS) consists of the triad: rheumatoid arthritis (RA), leukopenia and splenomegaly. FS occurs in approximately 1% of patients with RA.'
    explanation: The literature confirms that Felty's Syndrome is a hematologic condition associated with rheumatoid arthritis, occurring occasionally (approximately 1% of patients with RA).
  - reference: PMID:12455813
    reference_title: "Hematological manifestations of rheumatoid arthritis."
    supports: SUPPORT
    snippet: The hematological manifestations can be conveniently categorized into the broad areas of; anemia, particularly NSAID induced iron deficiency anemia and the anemia of chronic disease, neutropenia, particularly Felty's syndrome and the large granular lymphocyte syndrome and drug induced neutropenia.
    explanation: The literature supports that Felty's Syndrome is a hematologic manifestation of rheumatoid arthritis, occurring occasionally.
  - reference: PMID:312016
    reference_title: "Felty's syndrome without splenomegaly."
    supports: SUPPORT
    snippet: Thus, patients with rheumatoid arthritis without overt splenic enlargement may have pathophysiologic Felty's syndrome, and in vitro studies such as these may be used to define this process.
    explanation: The literature supports that Felty's Syndrome is associated with rheumatoid arthritis, even in the absence of splenomegaly, indicating it as a hematologic condition.
- category: Musculoskeletal
  name: Joint Deformity
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Joint Deformity
    term:
      id: HP:0001367
      label: Abnormal joint morphology
- category: Musculoskeletal
  name: Reduced Mobility
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Reduced Mobility
    term:
      id: HP:0001288
      label: Gait disturbance
- category: Musculoskeletal
  name: Joint Swelling
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Synovial hypertrophy and effusion leading to joint swelling
  phenotype_term:
    preferred_term: Joint swelling
    term:
      id: HP:0001386
      label: Joint swelling
- category: Musculoskeletal
  name: Erosive Arthritis
  frequency: FREQUENT
  notes: Bone erosions visible on radiography, particularly in hands and feet
  phenotype_term:
    preferred_term: Arthritis
    term:
      id: HP:0001369
      label: Arthritis
- category: Musculoskeletal
  name: Tenosynovitis
  frequency: FREQUENT
  notes: Inflammation of tendon sheaths, particularly in wrists and fingers; may precede joint erosion
  phenotype_term:
    preferred_term: Tenosynovitis
    term:
      id: HP:6001438
      label: Tenosynovitis
  evidence:
  - reference: PMID:28460018
    reference_title: "Evaluation of the diagnostic accuracy of hand and foot MRI for early Rheumatoid Arthritis."
    supports: SUPPORT
    snippet: "MRI-detected tenosynovitis was associated with RA development independent of other types of MRI-detected inflammation [odds ratio (OR) = 7.5, 95% CI: 2.4, 23]"
    explanation: Study demonstrates tenosynovitis is independently associated with RA development (OR 7.5), confirming it as a key early feature.
- category: Musculoskeletal
  name: Flexion Contracture
  frequency: FREQUENT
  notes: Fixed flexion deformity of joints due to chronic synovitis and fibrosis
  phenotype_term:
    preferred_term: Flexion contracture
    term:
      id: HP:0001371
      label: Flexion contracture
- category: Musculoskeletal
  name: Cervical Spine Instability
  frequency: OCCASIONAL
  notes: >-
    Atlantoaxial subluxation due to pannus erosion of the transverse ligament; can
    compromise the spinal cord. Cervical spine involvement of any kind is reported
    in up to 80% of RA patients, while symptomatic atlantoaxial instability is
    considerably less common.
  phenotype_term:
    preferred_term: Atlantoaxial instability
    term:
      id: HP:0003467
      label: Atlantoaxial instability
  evidence:
  - reference: PMID:25151973
    reference_title: "Cervical spine involvement in rheumatoid arthritis--a systematic review."
    supports: SUPPORT
    snippet: "Rheumatoid arthritis (RA) is a systemic chronic inflammatory disorder that can compromise the cervical spine in up to 80% of the cases."
    explanation: Systematic review demonstrates high prevalence of cervical spine involvement in RA, with atlantoaxial subluxation being the most common form.
  - reference: PMID:33609792
    reference_title: "Rheumatoid arthritis: Extra-articular manifestations and comorbidities."
    supports: SUPPORT
    snippet: "screening for depression, anxiety, atlantoaxial instability, and atherosclerosis"
    explanation: Atlantoaxial instability is listed as a screening target in RA management, confirming its clinical significance.
- category: Musculoskeletal
  name: Muscle Weakness
  frequency: FREQUENT
  notes: Disuse atrophy and inflammatory myopathy contributing to functional disability
  phenotype_term:
    preferred_term: Muscle weakness
    term:
      id: HP:0001324
      label: Muscle weakness
- category: Musculoskeletal
  name: Osteoporosis
  frequency: FREQUENT
  notes: Generalized bone loss due to systemic inflammation and glucocorticoid use
  phenotype_term:
    preferred_term: Osteoporosis
    term:
      id: HP:0000939
      label: Osteoporosis
  evidence:
  - reference: PMID:33199321
    reference_title: "Rheumatoid arthritis and bone health."
    supports: SUPPORT
    snippet: "Both inflammation and corticosteroids, however, have an adverse effect on bone mineral density, potentially resulting in osteoporosis and an increased risk of fractures."
    explanation: Review confirms that RA patients face osteoporosis from both systemic inflammation and corticosteroid therapy.
- category: Hematologic
  name: Anemia of Chronic Disease
  frequency: FREQUENT
  notes: Normochromic normocytic anemia driven by IL-6/hepcidin axis; prevalence 33-60%
  phenotype_term:
    preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
  evidence:
  - reference: PMID:15050886
    reference_title: "Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature."
    supports: SUPPORT
    snippet: "Anemia is a common comorbidity in individuals with rheumatoid arthritis (RA). In fact, anemia of the type characterized by low serum iron concentrations in conjunction with adequate iron stores is frequently associated with RA and has served as a model for anemia of chronic disease."
    explanation: Systematic review reports 33-60% prevalence of anemia in RA, establishing it as a frequent comorbidity.
  - reference: PMID:20851655
    reference_title: "Rheumatoid anemia."
    supports: SUPPORT
    snippet: "Rheumatoid anemia is a typical example of anemia of chronic disease."
    explanation: Review establishes rheumatoid anemia as the prototypical anemia of chronic disease, mediated by IL-6 and hepcidin.
- category: Neurologic
  name: Carpal Tunnel Syndrome
  frequency: OCCASIONAL
  notes: Median nerve compression from wrist synovitis and tenosynovitis
  phenotype_term:
    preferred_term: Carpal tunnel syndrome
    term:
      id: HP:0012181
      label: Entrapment neuropathy
  evidence:
  - reference: PMID:39343950
    reference_title: "Causal relationship between rheumatoid arthritis and carpal tunnel syndrome: a bidirectional two-sample Mendelian randomization study."
    supports: SUPPORT
    snippet: "Our results showed that RA patients have a higher risk of getting CTS regardless of whether the ebi database (IVW, OR = 1.045, 95% CI: 1.016-1.075, P = 0.002) or the GEO database (IVW, OR = 1.001, 95% CI: 1.001-1.002, P = 0.001) is selected for CTS data."
    explanation: Mendelian randomization confirms causal relationship between RA and increased carpal tunnel syndrome risk.
- category: Neurologic
  name: Peripheral Neuropathy
  frequency: OCCASIONAL
  notes: Sensorimotor neuropathy from vasculitis of the vasa nervorum
  phenotype_term:
    preferred_term: Peripheral neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
  evidence:
  - reference: PMID:24331794
    reference_title: "Vasculitic neuropathies."
    supports: SUPPORT
    snippet: "They are common in patients with primary systemic vasculitis and are seen in vasculitis secondary to disorders such as rheumatoid arthritis, viral infections, and diabetic inflammatory neuropathies."
    explanation: Vasculitic neuropathies are explicitly noted in RA as secondary vasculitis.
  - reference: PMID:33609792
    reference_title: "Rheumatoid arthritis: Extra-articular manifestations and comorbidities."
    supports: SUPPORT
    snippet: "Central and peripheral nervous system involvement is usually due to small vessel vasculitis, joint damage, or drug toxicity."
    explanation: Peripheral nervous system involvement in RA is attributed to vasculitis and structural damage.
- category: Extra-articular
  name: Vasculitis
  frequency: OCCASIONAL
  notes: Rheumatoid vasculitis affecting small and medium vessels; associated with seropositive, long-standing disease
  phenotype_term:
    preferred_term: Vasculitis
    term:
      id: HP:0002633
      label: Vasculitis
  evidence:
  - reference: PMID:33609792
    reference_title: "Rheumatoid arthritis: Extra-articular manifestations and comorbidities."
    supports: SUPPORT
    snippet: "Central and peripheral nervous system involvement is usually due to small vessel vasculitis, joint damage, or drug toxicity."
    explanation: Small vessel vasculitis is recognized as a cause of neurological and other extra-articular manifestations in RA.
- category: Extra-articular
  name: Episcleritis
  frequency: OCCASIONAL
  notes: Inflammation of the episcleral tissue; less severe than scleritis
  phenotype_term:
    preferred_term: Episcleritis
    term:
      id: HP:0100534
      label: Episcleritis
- category: Extra-articular
  name: Pleural Effusion
  frequency: OCCASIONAL
  notes: Exudative pleural effusion with low glucose and high LDH
  phenotype_term:
    preferred_term: Pleural effusion
    term:
      id: HP:0002202
      label: Pleural effusion
  evidence:
  - reference: PMID:33609792
    reference_title: "Rheumatoid arthritis: Extra-articular manifestations and comorbidities."
    supports: SUPPORT
    snippet: "The second major cause of death in patients with RA is respiratory disease, which occurs in 30-40% of patients. RA may affect the lung interstitium, airways, and pleurae"
    explanation: Pleural involvement is explicitly listed among the respiratory manifestations of RA.
- category: Extra-articular
  name: Raynaud Phenomenon
  frequency: OCCASIONAL
  notes: Vasospastic episodes in digits; may indicate underlying vasculitis
  phenotype_term:
    preferred_term: Raynaud phenomenon
    term:
      id: HP:0030880
      label: Raynaud phenomenon
- category: Extra-articular
  name: Lymphadenopathy
  frequency: OCCASIONAL
  notes: Reactive lymph node enlargement reflecting systemic immune activation
  phenotype_term:
    preferred_term: Lymphadenopathy
    term:
      id: HP:0002716
      label: Lymphadenopathy
- category: Cardiovascular
  name: Accelerated Atherosclerosis
  frequency: FREQUENT
  notes: Chronic inflammation drives premature cardiovascular disease; RA patients have 2x risk of myocardial infarction
  phenotype_term:
    preferred_term: Accelerated atherosclerosis
    term:
      id: HP:0004943
      label: Accelerated atherosclerosis
  evidence:
  - reference: PMID:33609792
    reference_title: "Rheumatoid arthritis: Extra-articular manifestations and comorbidities."
    supports: SUPPORT
    snippet: "Cardiovascular (CV) disease is the most common cause of death in patients with RA. Compared to the general population, patients with RA have twice the risk of myocardial infarction and up to 50% increased CV mortality risk."
    explanation: Review quantifies the excess cardiovascular risk in RA as 2-fold for MI and 50% increased CV mortality.
- name: "Myocardial infarction"
  category: Cardiovascular
  description: "Rheumatoid arthritis accelerates atherosclerotic cardiovascular disease, conferring roughly double the risk of myocardial infarction."
  phenotype_term:
    preferred_term: "Myocardial infarction"
    term:
      id: HP:0001658
      label: "Myocardial infarction"
  evidence:
  - reference: PMID:33609792
    reference_title: "Rheumatoid arthritis: Extra-articular manifestations and comorbidities."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "patients with RA have twice the risk of myocardial infarction"
    explanation: "This review of RA extra-articular disease states patients have twice the risk of myocardial infarction."
- name: "Interstitial pneumonitis"
  category: Respiratory
  description: "Interstitial lung disease is a major pulmonary extra-articular manifestation of rheumatoid arthritis."
  phenotype_term:
    preferred_term: "Interstitial pneumonitis"
    term:
      id: HP:0006515
      label: "Interstitial pneumonitis"
  evidence:
  - reference: PMID:33609792
    reference_title: "Rheumatoid arthritis: Extra-articular manifestations and comorbidities."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "RA may affect the lung interstitium, airways, and pleurae"
    explanation: "The review notes RA may affect the lung interstitium, supporting interstitial pneumonitis."
- name: "Pleuritis"
  category: Respiratory
  description: "Pleural inflammation is a recognized respiratory extra-articular manifestation of rheumatoid arthritis."
  phenotype_term:
    preferred_term: "Pleuritis"
    term:
      id: HP:0002102
      label: "Pleuritis"
  evidence:
  - reference: PMID:33609792
    reference_title: "Rheumatoid arthritis: Extra-articular manifestations and comorbidities."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "RA may affect the lung interstitium, airways, and pleurae"
    explanation: "The review notes RA may affect the pleurae, supporting pleuritis."
biochemical:
- name: Rheumatoid Factor (RF)
  presence: Positive
  subtype: Seropositive RA
  evidence:
  - reference: PMID:1757925
    reference_title: "Rheumatoid factors antedating clinical rheumatoid arthritis."
    supports: SUPPORT
    snippet: RF represent a key element in the rheumatoid inflammatory process. Their occurrence in preillness specimens suggests that they may have a primary role in the pathogenesis of the disease.
    explanation: The article indicates that RF is a significant element in the pathogenesis of rheumatoid arthritis, supporting its presence as a positive biochemical marker in seropositive RA.
  - reference: PMID:34675934
    reference_title: "Identification of a Novel Serological Marker in Seronegative Rheumatoid Arthritis Using the Peptide Library Approach."
    supports: SUPPORT
    snippet: The definition of seropositive or seronegative RA is based on the presence or absence of rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPAs).
    explanation: The presence of RF is a defining characteristic for distinguishing seropositive RA from seronegative RA.
  - reference: PMID:26199263
    reference_title: "Rheumatoid Factor, Anti-Cyclic Citrullinated Peptide Antibody, C-Reactive Protein, and Erythrocyte Sedimentation Rate for the Clinical Diagnosis of Rheumatoid Arthritis."
    supports: SUPPORT
    snippet: We observed significant differences in RF, anti-CCP antibody, CRP, and ESR concentrations between the RA and control groups (P <.01). The sensitivity, specificity, and accuracy in the diagnosis of RA were 91.0%, 74.4%, and 87.0%, respectively, for RF.
    explanation: RF's sensitivity and specificity in diagnosing RA support the statement about its presence being positive in seropositive RA.
- name: Anti-Cyclic Citrullinated Peptide (anti-CCP) Antibodies
  presence: Positive
  subtype: Seropositive RA
  evidence:
  - reference: PMID:20072731
    reference_title: "The value of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: do they imply new risk factors?"
    supports: SUPPORT
    snippet: A cohort of 937 patients with RA was studied ... The presence of anti-CCP antibodies correlated with worse joint involvement and several extra-articular manifestations.
    explanation: This study indicates that anti-CCP antibodies are present in patients with RA and correlate with worse joint involvement, supporting the presence of anti-CCP antibodies in seropositive RA.
  - reference: PMID:31656153
    reference_title: "Rheumatoid Arthritis: Seropositivity versus Seronegativity; A Comparative Cross-sectional Study Arising from Moroccan Context."
    supports: SUPPORT
    snippet: RA seronegativity is described as the absence of both RF and ACPA, while seropositivity is recognized by the presence of at least one of the two antibodies.
    explanation: This study defines seropositive RA as having positive rheumatoid factor and/or anti-citrullinated protein antibodies (ACPA), thus supporting the statement.
  - reference: PMID:31848495
    reference_title: "[Clinical characteristics of psoriatic arthritis with positive rheumatoid factor or anti-cyclic citrullinated peptide antibody]."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: RF and anti-CCP antibodies can be detected in the serum of some PsA patients.
    explanation: Concerns psoriatic arthritis, not RA; retained only to record that anti-CCP positivity is not wholly specific to RA.
  - reference: PMID:34404786
    reference_title: "Single-cell sequencing of immune cells from anticitrullinated peptide antibody positive and negative rheumatoid arthritis."
    supports: SUPPORT
    snippet: We profile CD45(+) hematopoietic cells from peripheral blood or synovial tissues from both ACPA+ and ACPA- RA patients by single-cell RNA sequencing...
    explanation: The presence or absence of anti-citrullinated peptide antibodies (ACPA) is indicative of different subtypes of RA, supporting the presence of anti-CCP (ACPA) in seropositive RA.
  - reference: PMID:36319009
    reference_title: "Effects of Aging on Rheumatoid Factor and Anticyclic Citrullinated Peptide Antibody Positivity in Patients With Rheumatoid Arthritis."
    supports: PARTIAL
    snippet: Positivity rates of RF and anti-CCP almost linearly decreased along with the increase in age at RA diagnosis.
    explanation: While this study addresses factors influencing anti-CCP positivity, it does not exclusively confirm or refute the statement as a whole but provides partial support.
  - reference: PMID:33461622
    reference_title: "Serum biomarker panel for the diagnosis of rheumatoid arthritis."
    supports: SUPPORT
    snippet: These serological factors are diagnostic markers of RA; however, their sensitivity and specificity for prediction warrant improvement for an early and accurate diagnosis.
    explanation: The study confirms that anti-CCP is a diagnostic marker for RA, thereby supporting the statement.
  - reference: PMID:18300568
    reference_title: "Associations between serum anti-CCP antibody, rheumatoid factor levels and HLA-DR4 expression in Hungarian patients with rheumatoid arthritis."
    supports: SUPPORT
    snippet: Of the 53 patients 33 (62%) were positive for anti-CCP antibody.
    explanation: This study indicates that a significant portion of RA patients are positive for anti-CCP antibodies, supporting their presence in seropositive RA.
- name: Erythrocyte Sedimentation Rate (ESR)
  presence: Elevated
  evidence:
  - reference: PMID:16818462
    reference_title: "Raised erythrocyte sedimentation rate signals heart failure in patients with rheumatoid arthritis."
    supports: SUPPORT
    snippet: In patients with rheumatoid arthritis who developed heart failure, the proportion with ESR >/=40 mm/h was highest (23%) during the 6-month period immediately preceding the new-onset heart failure, as compared with the average ESR during the entire remaining follow-up period, both before and after heart failure (10.6%; p<0.01).
    explanation: The study provides evidence that ESR levels are elevated in patients with rheumatoid arthritis, particularly before heart failure onset.
  - reference: PMID:26199263
    reference_title: "Rheumatoid Factor, Anti-Cyclic Citrullinated Peptide Antibody, C-Reactive Protein, and Erythrocyte Sedimentation Rate for the Clinical Diagnosis of Rheumatoid Arthritis."
    supports: SUPPORT
    snippet: We observed significant differences in RF, anti-CCP antibody, CRP, and ESR concentrations between the RA and control groups (P <.01).
    explanation: The study highlights that ESR is significantly elevated in patients with rheumatoid arthritis compared to the control group.
  - reference: PMID:34958010
    reference_title: "Preoperative erythrocyte sedimentation rate in patients with rheumatoid arthritis predicts deep vein thrombosis following total knee arthroplasty."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: ESR was significantly correlated with DVT risk after TKA (OR = 1.844, 95% CI = 1.022-2.981, P = 0.019).
    explanation: Shows ESR carries prognostic information after total knee arthroplasty; it does not itself establish that ESR is elevated in RA, so support is PARTIAL.
- name: C-Reactive Protein (CRP)
  presence: Elevated
  evidence:
  - reference: PMID:36539129
    reference_title: "EVALUATION OF SERUM LEVELS OF INTERLEUKIN-6, FETUIN-A, LIPOCALIN-2, AND C-REACTIVE PROTEIN IN RHEUMATOID ARTHRITIS PATIENTS."
    supports: PARTIAL
    snippet: CRP has been widely accepted as a systemic inflammatory marker.
    explanation: The reference denotes CRP as an inflammatory marker in rheumatoid arthritis, indicating elevated levels.
  - reference: PMID:28393498
    reference_title: "Impact of Obesity and Adiposity on Inflammatory Markers in Patients With Rheumatoid Arthritis."
    supports: SUPPORT
    snippet: The C-reactive protein (CRP) level and erythrocyte sedimentation rate (ESR) are important disease activity biomarkers in rheumatoid arthritis (RA).
    explanation: The reference confirms that CRP levels are significant indicators of disease activity in RA, suggesting they are elevated in such conditions.
  - reference: PMID:26199263
    reference_title: "Rheumatoid Factor, Anti-Cyclic Citrullinated Peptide Antibody, C-Reactive Protein, and Erythrocyte Sedimentation Rate for the Clinical Diagnosis of Rheumatoid Arthritis."
    supports: SUPPORT
    snippet: We observed significant differences in RF, anti-CCP antibody, CRP, and ESR concentrations between the RA and control groups (P <.01).
    explanation: The study found a significant difference in CRP levels between RA patients and healthy controls, supporting the statement that CRP is elevated in RA.
  - reference: PMID:21468143
    reference_title: "C-reactive protein in rheumatology: biology and genetics."
    supports: PARTIAL
    snippet: Measurement of serum C-reactive protein (CRP) level is in widespread clinical use as a sensitive marker of inflammation.
    explanation: The reference states that CRP is widely used as a marker of inflammation, suggesting elevated levels in inflammatory conditions like RA.
genetic:
- name: HLA-DRB1
  association: Associated with increased risk
  notes: HLA-DRB1 shared epitope alleles present citrullinated peptides to CD4+ T cells, representing the major genetic risk factor for seropositive RA
  evidence:
  - reference: PMID:24447879
    reference_title: "Association study of human leukocyte antigen-DRB1 alleles with rheumatoid arthritis in Algerian patients."
    supports: SUPPORT
    snippet: HLA-DRB1*04 was found to have increased frequency in the RA group compared to controls (P < 0.001, OR = 3.14)...HLA-DRB1*04:05 was associated with RA (P = 0.005, OR = 3.41)
    explanation: The study shows an increased frequency of HLA-DRB1*04 and HLA-DRB1*04:05 in the RA group, indicating an association with increased risk.
  - reference: PMID:32638005
    reference_title: "The genetics of rheumatoid arthritis."
    supports: SUPPORT
    snippet: This review identifies the most significant genetic variants associated with RA susceptibility to date, with particular focus on the contribution of the HLA class II genes across different ethnic groups.
    explanation: The review discusses the significant role of HLA-DRB1 in RA susceptibility.
  - reference: PMID:16542468
    reference_title: "HLA-DRB1 genes and extraarticular rheumatoid arthritis."
    supports: SUPPORT
    snippet: HLA-DR alleles such as HLA-DR4 and HLA-DR1 are associated with the risk to develop RA.
    explanation: HLA-DR4, a subtype of HLA-DRB1, is associated with an increased risk of developing RA.
  - reference: PMID:32370106
    reference_title: "Current Understanding of an Emerging Role of HLA-DRB1 Gene in Rheumatoid Arthritis-From Research to Clinical Practice."
    supports: SUPPORT
    snippet: Association studies of the HLA-DRB1 gene clearly indicate its importance in RA morbidity.
    explanation: The review presents the current understanding of HLA-DRB1's role in increasing the risk of RA.
  - reference: PMID:24336335
    reference_title: "Genetic risk scores and number of autoantibodies in patients with rheumatoid arthritis."
    supports: SUPPORT
    snippet: Certain HLA-DRB1 alleles and single-nucleotide polymorphisms (SNPs) are associated with rheumatoid arthritis (RA).
    explanation: The study reinforces the association of HLA-DRB1 alleles with RA.
  - reference: PMID:3067866
    reference_title: "Rheumatoid arthritis."
    supports: SUPPORT
    snippet: Part of this genetic predisposition is accounted for by genes within the MHC where there is a well-documented association with HLA-DR4.
    explanation: The study mentions the association of HLA-DR4, a subtype of HLA-DRB1, with RA.
  - reference: PMID:36155967
    reference_title: "Genetic, social, and environmental risk factors in rheumatoid arthritis-associated interstitial lung disease."
    supports: PARTIAL
    snippet: We evaluated whether RA-ILD is associated with these genetic variants and HLA-DRB1 shared epitope (SE) alleles in a large RA cohort stratified by race and smoking history.
    explanation: The study discusses the association of HLA-DRB1 SE alleles with RA-ILD.
- name: PTPN22
  association: Associated with increased risk
  evidence:
  - reference: PMID:30957405
    reference_title: "Association between PTPN22-1123G/C and susceptibility to rheumatoid arthritis: A systematic review and meta-analysis."
    supports: SUPPORT
    snippet: The overall effect of PTPN22-1123 on RA risk in all genetic random models showed significant positive associations.
    explanation: The study found significant positive associations between PTPN22 genetic variations and increased risk of rheumatoid arthritis.
  - reference: PMID:15790351
    reference_title: "Pathways to gene identification in rheumatoid arthritis: PTPN22 and beyond."
    supports: SUPPORT
    snippet: A functional variant (R620W) of the intracellular protein tyrosine phosphatase N22 (PTPN22) has now been conclusively shown to confer approximately two-fold risk for seropositive RA as well as several other autoimmune disorders.
    explanation: The variant R620W of PTPN22 is associated with a significantly increased risk of rheumatoid arthritis.
  - reference: PMID:15838240
    reference_title: "Understanding the genetic contribution to rheumatoid arthritis."
    supports: SUPPORT
    snippet: The second risk factor for rheumatoid arthritis, the PTPN22 polymorphism, has been identified.
    explanation: The PTPN22 polymorphism has been identified as a genetic risk factor for rheumatoid arthritis.
- name: STAT4
  association: Associated with increased risk
  evidence:
  - reference: PMID:30864557
    reference_title: "Studying the Association between STAT4 Gene Polymorphism and Susceptibility to Rheumatoid Arthritis Disease: An Updated Meta-Analysis."
    supports: SUPPORT
    snippet: Herein, we found a significant positive association between minor T allele as well as different genotypes with the risk of RA.
    explanation: The study found a significant positive association between the STAT4 gene rs7574865 SNP and the risk of rheumatoid arthritis (RA).
  - reference: PMID:20453440
    reference_title: "Association of IRF5, STAT4 and BLK with systemic lupus erythematosus and other rheumatic diseases."
    supports: SUPPORT
    snippet: We and other investigators also found that IRF5, STAT4 and BLK are associated not only with SLE, but also rheumatoid arthritis and systemic sclerosis.
    explanation: The literature supports an association between the STAT4 gene and increased risk of rheumatoid arthritis.
- name: CTLA4
  association: Associated with increased risk
  evidence:
  - reference: PMID:34339393
    reference_title: "Association between CTLA-4 gene polymorphism and risk of rheumatoid arthritis: a meta-analysis."
    supports: SUPPORT
    snippet: This meta-analysis confirmed that rs3087243 and rs231775 polymorphism were associated with the risk of RA in both overall population and ethnic-specific analysis, but there was no association between rs5742909 polymorphism and RA risk
    explanation: The meta-analysis provides evidence that CTLA-4 gene polymorphisms are associated with an increased risk of rheumatoid arthritis.
  - reference: PMID:35758965
    reference_title: "Three key genes expression profiling in Egyptian rheumatoid arthritis patients."
    supports: SUPPORT
    snippet: There was a significantly higher median (inter-quartile range) expression of CTLA-4 and CCL2 in RA patients in comparison to controls (P < 0.05)
    explanation: The study found significantly higher expression of CTLA-4 in RA patients, supporting the association of CTLA-4 with increased RA risk.
  - reference: PMID:11196709
    reference_title: "CTLA-4 in autoimmune diseases--a general susceptibility gene to autoimmunity?"
    supports: SUPPORT
    snippet: For most autoimmune disorders... the gene encoding cytotoxic T lymphocyte-associated antigen 4 (CTLA4) has been suggested as a candidate gene for conferring susceptibility to autoimmunity.
    explanation: The article discusses CTLA4 as a candidate gene for susceptibility to autoimmune diseases, including rheumatoid arthritis.
- name: PADI4
  association: Associated with increased risk
  notes: Encodes peptidylarginine deiminase 4, the enzyme responsible for protein citrullination in neutrophil extracellular traps and immune cells, generating ACPA-target neoepitopes
  evidence:
  - reference: PMID:17893996
    reference_title: "Citrullination by peptidylarginine deiminase in rheumatoid arthritis."
    supports: SUPPORT
    snippet: peptidylarginine deiminase (gene name abbreviated to PADI, protein name abbreviated to PAD) type 4 is the one of the non-HLA genetic factors involved in RA via citrullination
    explanation: This review identifies PADI4 as a key non-HLA genetic susceptibility factor for RA, demonstrating the link between citrullination of proteins and generation of autoantigens targeted by anti-citrullinated protein antibodies.
- name: PADI2
  association: Associated with increased risk
  notes: Encodes peptidylarginine deiminase 2, contributes to citrullination at mucosal sites and in inflammatory cells
- name: TNF
  association: Central proinflammatory cytokine
  notes: Master cytokine driving synovitis, fibroblast-like synoviocyte activation, and leukocyte recruitment; therapeutic target of TNF inhibitors
- name: IL6R
  association: Mediates IL-6 signaling
  notes: IL-6 receptor mediates JAK/STAT signaling driving systemic and synovial inflammation; therapeutic target (tocilizumab)
- name: TYK2
  association: Associated with increased risk
  notes: Tyrosine kinase 2, part of JAK/STAT signaling pathway; mediates cytokine signals including IL-6 and interferons
- name: BACH2
  association: GWAS
  notes: Transcription factor regulating Treg/effector T cell balance and B cell class switching
- name: TNFAIP3
  association: GWAS
  notes: Encodes A20, a ubiquitin-editing enzyme that negatively regulates NF-kB signaling
- name: STAT3
  association: GWAS
  notes: Signal transducer mediating Th17 differentiation via JAK-STAT pathway
- name: IL10
  association: GWAS
  notes: Anti-inflammatory cytokine critical for immune tolerance
- name: CD28
  association: GWAS
  notes: T cell co-stimulatory receptor required for T cell activation
- name: EGR2
  association: GWAS
  notes: Transcription factor involved in T cell anergy and peripheral tolerance
- name: ETS1
  association: GWAS
  notes: Transcription factor regulating T and B cell development and immune cell differentiation
- name: IRF4
  association: GWAS
  notes: Transcription factor essential for Th17 and Th2 cell differentiation and plasma cell development
- name: IRF8
  association: GWAS
  notes: Interferon regulatory factor controlling myeloid cell development and type I interferon response
- name: SATB1
  association: GWAS
  notes: Chromatin organizer regulating T cell development and lineage commitment
- name: IKZF1
  association: GWAS
  notes: Ikaros transcription factor essential for lymphocyte development and differentiation
- name: REL
  association: GWAS
  notes: NF-kB subunit c-Rel controlling lymphocyte activation and survival
- name: PRDM1
  association: GWAS
  notes: Blimp-1 transcription factor regulating T cell and B cell terminal differentiation
- name: IL21R
  association: GWAS
  notes: IL-21 receptor mediating T and B cell activation and differentiation
environmental:
- name: Smoking
  notes: Increases risk and severity
  exposure_term:
    preferred_term: Tobacco smoking exposure
    term:
      id: ECTO:6000029
      label: exposure to tobacco smoking
  evidence:
  - reference: PMID:22609003
    reference_title: "Tobacco and other environmental risk factors in rheumatoid arthritis."
    supports: SUPPORT
    snippet: Smoking is associated with an increased risk of developing seropositive RA (RF and/or ACPA). Recent studies show that tobacco smoking can influence disease phenotype, with the development of more aggressive disease and greater joint damage.
    explanation: The literature indicates that smoking increases the risk of developing seropositive RA and may lead to more severe disease outcomes, which aligns with the statement.
  - reference: PMID:12860726
    reference_title: "Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years."
    supports: SUPPORT
    snippet: In a multivariate analysis the main predictors of severe ExRA were smoking at RA diagnosis (risk ratio (RR)=2.94; 95% confidence interval (95% CI) 1.68 to 5.13).
    explanation: This reference indicates smoking as a significant predictor of severe extra-articular manifestations in RA, supporting the statement about severity.
  - reference: PMID:36155967
    reference_title: "Genetic, social, and environmental risk factors in rheumatoid arthritis-associated interstitial lung disease."
    supports: SUPPORT
    snippet: MUC5B and TOLLIP single nucleotide polymorphisms (SNPs) and cigarette smoking were associated with rheumatoid arthritis-interstitial lung disease (RA-ILD).
    explanation: Smoking is listed as a risk factor for RA and its associated complications, such as interstitial lung disease.
- name: Infections
  notes: Potential trigger for disease onset
  evidence:
  - reference: PMID:28516867
    reference_title: "The link between Proteus mirabilis, environmental factors and autoantibodies in rheumatoid arthritis."
    supports: PARTIAL
    snippet: Extensive data supports the roles of genetic, environmental and microbial factors in the triggering and development of this disease. Proteus mirabilis is considered as the main microbial culprit in the causation of RA.
    explanation: This reference supports the role of infections, specifically microbial factors, as potential environmental triggers for the onset of rheumatoid arthritis.
  - reference: PMID:32582191
    reference_title: "Infectious Triggers in Periodontitis and the Gut in Rheumatoid Arthritis (RA): A Complex Story About Association and Causality."
    supports: PARTIAL
    snippet: In conclusion, we retrieved more than one line of evidence for mucosal sites and different microbial taxa to be potentially involved in the development of RA.
    explanation: This reference provides multiple lines of evidence suggesting that infections, specifically from various microbial taxa, are potential contributors to the onset of rheumatoid arthritis.
  - reference: PMID:35897715
    reference_title: "Interplay of Environmental, Individual and Genetic Factors in Rheumatoid Arthritis Provocation."
    supports: PARTIAL
    snippet: Possible mechanisms involving environmental and individual factors in RA pathogenesis were analyzed, namely, infections, mental stress, sleep deprivation ecology, age, perinatal and gender factors, eating habits, obesity and smoking.
    explanation: This reference explicitly includes infections among the environmental factors that may contribute to the onset of RA.
  exposure_term:
    preferred_term: Infectious agent exposure
    term:
      id: ECTO:3000000
      label: exposure to organism
treatments:
- name: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  description: Reduce pain and inflammation.
  evidence:
  - reference: PMID:11899747
    reference_title: "Advances in anti-inflammatory therapy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: NSAID toxicity mostly affected the GI tract. There was a similar incidence of GI-related adverse events between patients with and patients without GI protection, mainly dyspepsia and nausea. NSAIDs have the potential to cause adverse events in the GI tract.
    explanation: Characterises the gastrointestinal toxicity that constrains NSAID use; it addresses safety rather than the efficacy claim in this treatment description.
  - reference: PMID:23083758
    reference_title: "Therapeutic controversies in spondyloarthritis: nonsteroidal anti-inflammatory drugs."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: NSAIDs reduce pain and stiffness effectively in most patients, are able to reduce systemic and local inflammation, and can inhibit progression of structural damage in the spine.
    explanation: Documents NSAID efficacy for pain, stiffness and inflammation, but in spondyloarthritis rather than RA, so support is PARTIAL.
  treatment_term:
    preferred_term: NSAID therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: NSAID
      term:
        id: NCIT:C257
        label: Nonsteroidal Antiinflammatory Drug
- name: Disease-Modifying Antirheumatic Drugs (DMARDs)
  description: Slow disease progression and prevent joint damage (e.g., methotrexate, hydroxychloroquine).
  evidence:
  - reference: PMID:14969069
    reference_title: "Disease-modifying anti-rheumatic drug therapy and structural damage in early rheumatoid arthritis."
    supports: SUPPORT
    snippet: Disease-modifying anti-rheumatic drugs (DMARDs) used in combination appear to be more effective than monotherapies at reducing the rate of progressive joint damage during randomized controlled trials.
    explanation: This statement directly supports the idea that DMARDs slow disease progression and prevent joint damage.
  - reference: PMID:8601050
    reference_title: "Disease-modifying antirheumatic drugs. Potential effects in older patients."
    supports: SUPPORT
    snippet: Methotrexate is presently the most popular of the DMARDs for the treatment of rheumatoid arthritis. Methotrexate inhibits dihydrofolate reductase and adenosine release and has a secondary effect on cytokines and polymorphonuclear chemotaxis. It is highly metabolised within cells and remains there for prolonged periods.
    explanation: This excerpt indicates methotrexate's mechanisms in treating RA, affirming its role in slowing disease progression and preventing joint damage.
  - reference: PMID:25172238
    reference_title: "Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an \"anchor\" drug?"
    supports: SUPPORT
    snippet: According to the results of several head-to-head comparative trials against other synthetic DMARDs, MTX has been recognised as the 'anchor drug' for the treatment of RA.
    explanation: This confirms methotrexate's effectiveness as a primary treatment in managing RA, thus supporting the statement.
  - reference: PMID:35953230
    reference_title: "Treatment Guidelines in Rheumatoid Arthritis."
    supports: SUPPORT
    snippet: Key recommendations are to start effective treatment immediately with DMARDs to reduce disability; use effective doses of methotrexate (oral or subcutaneous) with folic acid as the initial treatment; rapidly escalate treatment with various DMARDs, if methotrexate alone is not effective in controlling rheumatoid arthritis.
    explanation: This supports the statement by advising DMARDs to prevent disease progression and joint damage.
  - reference: PMID:42362943
    reference_title: "2024 Update of the Asia-Pacific League of Associations for Rheumatology (APLAR) Recommendations for Rheumatoid Arthritis Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The recommendations address the selection of disease activity scores, initiation and intensification of therapy using csDMARDs and targeted therapies, and management of RA in patients at risk of reactivation of infectious diseases."
    explanation: The 2024 APLAR recommendations frame RA management around disease-activity-guided initiation and intensification of csDMARDs and targeted therapies (treat-to-target).
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
- name: Biologics
  description: Target specific components of the immune system (e.g., TNF-α inhibitors, IL-6 inhibitors).
  evidence:
  - reference: PMID:22166850
    reference_title: "Biologics-based therapy for the treatment of rheumatoid arthritis."
    supports: SUPPORT
    snippet: Rheumatoid arthritis (RA) remains a major clinical problem, but treatments involving biologics have revolutionized its management. They target pathogenically relevant cytokines such as tumor necrosis factor and immune cells such as B cells.
    explanation: This reference confirms that biologics used in the treatment of RA target specific components of the immune system, including cytokines like TNF-α.
  - reference: PMID:25697599
    reference_title: "Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases."
    supports: SUPPORT
    snippet: Anticytokine therapy for inflammatory diseases became a clinical reality with the introduction of tumor necrosis factor (TNF) inhibitors for the treatment of severe rheumatoid arthritis.
    explanation: The reference highlights that anticytokine therapies, including TNF inhibitors, are used in RA treatment, thus supporting the statement.
  - reference: PMID:32550671
    reference_title: "Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update."
    supports: SUPPORT
    snippet: Cytokine blockers were the first to be developed and rapidly expanded. They include agents that act against tumor necrosis factor alpha (TNF-α)... and interleukin (IL) 6 (tocilizumab and sarilumab).
    explanation: The reference supports that biologics used for RA treatment include TNF-α inhibitors and IL-6 inhibitors, which target specific components of the immune system.
  treatment_term:
    preferred_term: biologic therapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
- name: JAK Inhibitors
  description: >-
    Oral targeted synthetic DMARDs (tofacitinib, baricitinib, upadacitinib, and
    related agents) that inhibit Janus kinases, blocking JAK/STAT signal
    transduction downstream of multiple pro-inflammatory cytokine receptors
    (notably IL-6). Used in rheumatoid arthritis, typically after inadequate
    response to conventional synthetic or biologic DMARDs.
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: JAK/STAT Signaling
    treatment_effect: INHIBITS
    description: >-
      JAK inhibitors block Janus kinase catalytic activity, suppressing the
      IL-6-driven JAK/STAT signaling that is implicated in RA synovial
      inflammation and disease progression.
    evidence:
    - reference: PMID:35367240
      reference_title: "Underpinning IL-6 biology and emphasizing selective JAK blockade as the potential alternate therapeutic intervention for rheumatoid arthritis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This review discusses the history of research into IL-6 biology and therapies that target the IL-6 driven JAK/STAT pathway, including the successes, challenges, and drawbacks, emphasizing RA."
      explanation: The review frames JAK inhibitors as therapies that target the IL-6-driven JAK/STAT pathway in RA, supporting the INHIBITS link to the JAK/STAT Signaling node.
  evidence:
  - reference: PMID:32550671
    reference_title: "Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Janus kinase (JAK) inhibitors (tofacitinib, baricitinib, and upadacitinib) and phosphodiesterase 4 inhibitors (apremilast) form this group."
    explanation: Identifies tofacitinib, baricitinib, and upadacitinib as the JAK-inhibitor small-molecule class used in systemic autoimmune conditions including RA.
  - reference: PMID:35367240
    reference_title: "Underpinning IL-6 biology and emphasizing selective JAK blockade as the potential alternate therapeutic intervention for rheumatoid arthritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "JAK inhibitors, namely Tofacitinib, Baricitinib, Decernotinib, Upadacitinib, Peficitinib, and Filgotinib, have demonstrated clinical efficacy in recent decades as an alternative therapeutic strategy to abrogate IL-6 mediated aberrant activity in RA."
    explanation: Establishes that JAK inhibitors have demonstrated clinical efficacy in RA, supporting their inclusion as a targeted synthetic DMARD treatment class.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: tofacitinib
      term:
        id: CHEBI:71200
        label: tofacitinib
- name: Glucocorticoids
  description: Potent anti-inflammatory agents used for short-term control of flares or as a bridge therapy.
  evidence:
  - reference: PMID:28043173
    reference_title: "Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis."
    supports: PARTIAL
    snippet: Glucocorticoids - be it conventional or modified/delayed-release formulations - have so far been convincing in clinical practice, and their widespread use will therefore continue.
    explanation: The literature supports the use of glucocorticoids for the treatment of rheumatoid arthritis, highlighting their efficacy. However, it does not specify that they are used for short-term control of flares or as bridge therapy, thus only partially supporting the precise conditions mentioned in the statement.
  - reference: PMID:24527481
    reference_title: "Rheumatoid arthritis: early treatment with corticosteroids and nonsteroidal anti-inflammatory drugs."
    supports: PARTIAL
    snippet: The family physician plays several important roles in the management of patients with RA by early diagnosis of RA, with initiation of synthetic DMARD therapy, and in long-term follow-up to minimize complications of DMARD therapy and its impact on patient comorbidities.
    explanation: This reference mentions the management and use of various therapies for rheumatoid arthritis, but it does not explicitly discuss the short-term use or glucocorticoids as bridge therapy, providing only partial support.
  - reference: PMID:29745893
    reference_title: "Cell therapies for refractory rheumatoid arthritis."
    supports: PARTIAL
    snippet: Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and disease-modifying antirheumatic drugs (DMARDs) are widely used to treat RA patients.
    explanation: This literature confirms the use of corticosteroids (which include glucocorticoids) in treating RA but does not specify their role as short-term or bridge therapy, thereby partially supporting the statement.
  treatment_term:
    preferred_term: systemic corticosteroid therapy
    term:
      id: NCIT:C122080
      label: Systemic Corticosteroid Therapy
- name: Physical Therapy
  description: Maintains joint mobility and strengthens surrounding muscles.
  evidence:
  - reference: PMID:15266230
    reference_title: "Physiotherapy in rheumatoid arthritis."
    supports: SUPPORT
    snippet: Physiotherapy and rehabilitation applications significantly augment medical therapy by improving the management of RA and reducing handicaps in daily living for patients with RA.
    explanation: The literature supports the effectiveness of physiotherapy in managing RA, including maintaining joint mobility and reducing disabilities.
  - reference: PMID:25748549
    reference_title: "Strengthening And stretching for Rheumatoid Arthritis of the Hand (SARAH). A randomised controlled trial and economic evaluation."
    supports: SUPPORT
    snippet: The exercise programme consisted of six sessions of strengthening and stretching exercises with a hand therapist, daily home exercises and strategies to maximise adherence.
    explanation: The results indicate that exercise programmes included in physical therapy can be effective in maintaining joint function and strengthening muscles in RA patients.
  - reference: PMID:9667624
    reference_title: "Dynamic exercise therapy in rheumatoid arthritis: a systematic review."
    supports: SUPPORT
    snippet: The results suggest that dynamic exercise therapy is effective in increasing aerobic capacity and muscle strength.
    explanation: Dynamic exercise therapy, a component of physical therapy, has been shown to improve muscle strength and maintain physical capacity in RA patients.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Physical Therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
discussions:
- discussion_id: gap_ra_synovial_lining_quiescence_induction
  prompt: >-
    Can the quiescent synovial lining program seen in RA remission be actively
    induced to suppress pathogenic fibroblast-myeloid niches, or is it only a
    marker that appears after inflammation has already resolved?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Synovial Hyperplasia
  - pathophysiology#Inflammatory Cytokine Production
  - pathophysiology#Cartilage and Bone Destruction
  rationale: >-
    The entry captures synovial hyperplasia and cytokine-driven joint
    destruction, but recent spatial and organoid studies indicate that
    fibroblast density, EGFR-CREB5 signaling, and myeloid-stromal niches may
    determine whether the lining adopts a homeostatic or invasive state. A
    causal experiment would distinguish remission biology that can be
    therapeutically induced from a passive correlate of low inflammation.
  proposed_experiments:
  - experiment_id: exp_ra_synovial_organoid_egfr_creb5_quiescence
    name: Human RA synovial organoid EGFR-CREB5 quiescence induction assay
    description: >-
      Build 3D human synovial organoids from RA fibroblast-like synoviocyte
      clusters, blood-derived myeloid precursors, and endothelial cells; tune
      fibroblast spatial density and inflammatory cytokine exposure; activate
      or inhibit HB-EGF-EGFR-CREB5 signaling; and test whether a quiescent
      lining program suppresses invasive, cytokine-producing fibroblast states.
    experiment_type:
      preferred_term: synovial organoid perturbation experiment
    model_systems:
    - name: Human RA synovial fibroblast-myeloid organoid
      description: >-
        Three-dimensional human synovial organoid containing RA
        fibroblast-like synoviocyte clusters, blood-derived myeloid precursors,
        and endothelial cells to reproduce lining and sublining niche
        architecture.
      experimental_model_type: ORGANOID
      namo_type: namo:Organoid
      organism:
        preferred_term: human
        term:
          id: NCBITaxon:9606
          label: Homo sapiens
      tissue_term:
        preferred_term: synovial membrane
        term:
          id: UBERON:0002018
          label: synovial membrane of synovial joint
      cell_types:
      - preferred_term: fibroblast-like synoviocyte
        term:
          id: CL:0000057
          label: fibroblast
      - preferred_term: macrophage
        term:
          id: CL:0000235
          label: macrophage
      - preferred_term: endothelial cell
        term:
          id: CL:0000115
          label: endothelial cell
      cell_source: RA synovial biopsy-derived fibroblasts plus blood-derived myeloid precursors
      culture_system: 3D matrix-embedded synovial organoid with controlled fibroblast density
    perturbations:
    - name: HB-EGF-EGFR-CREB5 axis activation or blockade
      target: pathophysiology#Synovial Hyperplasia
      description: >-
        Ligand stimulation, EGFR inhibition, and CREB5 activation or knockdown
        used to test whether proximity-sensing signaling actively specifies
        quiescent lining fibroblast differentiation.
      genes:
      - preferred_term: HBEGF
      - preferred_term: EGFR
      - preferred_term: CREB5
    - name: IL-1 beta and TGF-beta inflammatory fibroblast challenge
      target: pathophysiology#Inflammatory Cytokine Production
      description: >-
        Cytokine combination used to induce the invasive glycolytic RA-FLS
        state before or after quiescence-induction perturbations.
      biological_processes:
      - preferred_term: cytokine-mediated signaling pathway
        term:
          id: GO:0019221
          label: cytokine-mediated signaling pathway
    - name: TAK1 pathway blockade
      target: pathophysiology#Inflammatory Cytokine Production
      description: >-
        TAK1 inhibition used as a comparator for suppressing IL-1 beta/TGF-beta
        pathogenic fibroblast activation.
      gene:
        preferred_term: MAP3K7
    readouts:
    - name: Quiescent lining fibroblast differentiation
      target: pathophysiology#Synovial Hyperplasia
      description: PRG4, CLU, and PDPN lining markers versus proliferative fibrotic markers.
      assays:
      - preferred_term: spatial transcriptomic profiling
      - preferred_term: immunofluorescence assay
      direction: NEGATIVE
    - name: Pathogenic fibroblast invasion and matrix remodeling
      target: pathophysiology#Cartilage and Bone Destruction
      description: MMP, collagen, invasion, and synovial-growth readouts in the organoid matrix.
      biological_processes:
      - preferred_term: extracellular matrix organization
        term:
          id: GO:0030198
          label: extracellular matrix organization
      assays:
      - preferred_term: invasion assay
      - preferred_term: extracellular matrix immunostaining
      direction: POSITIVE
    - name: Myeloid-stromal inflammatory niche state
      target: pathophysiology#Inflammatory Cytokine Production
      description: Macrophage subset composition and FLS cytokine output after quiescence induction.
      biological_processes:
      - preferred_term: inflammatory response
        term:
          id: GO:0006954
          label: inflammatory response
      assays:
      - preferred_term: single-cell transcriptomic profiling
      - preferred_term: multiplex cytokine profiling
      direction: POSITIVE
    controls:
    - name: Healthy donor synovial organoid
      description: Matched organoid built from non-RA synovial fibroblast and myeloid compartments.
    - name: Low-density fibroblast organoid
      description: Density-control organoid expected to favor proliferative or fibrotic states.
    - name: Vehicle-treated RA synovial organoid
      description: RA organoid receiving vehicle rather than EGFR-CREB5 or TAK1 perturbation.
    decision_criterion: >-
      Active induction is supported if EGFR-CREB5 activation restores PRG4/CLU/
      PDPN lining markers and reduces invasive, glycolytic, and cytokine
      readouts even under IL-1 beta/TGF-beta challenge; passive-marker status
      is supported if quiescent markers appear only after inflammatory signals
      are removed.
    would_support:
    - pathophysiology#Synovial Hyperplasia
    - pathophysiology#Inflammatory Cytokine Production
    would_refute:
    - pathophysiology#Synovial Hyperplasia
    evidence:
    - reference: PMID:41427340
      reference_title: "Fibroblasts sense spatial proximity via an EGFR-CREB5 axis to restore quiescent synovial lining in remission rheumatoid arthritis."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Perturbation of the EGFR-CREB5 axis abolishes fibroblast proximity-sensing and blocks synovial lining fibroblast differentiation."
      explanation: >-
        Provides the specific proximity-sensing pathway that the proposed
        organoid experiment would test as an inducible remission mechanism.
    - reference: PMID:41333404
      reference_title: "The ontogeny of myeloid-stromal synovial tissue niches in rheumatoid arthritis."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "These organoids reproduced key synovial tissue features, including lining and sublining architecture and stromal-myeloid cell cluster composition."
      explanation: >-
        Supports feasibility of a human synovial organoid that preserves the
        tissue architecture needed to test lining-state restoration.
    - reference: PMID:41435749
      reference_title: "Immune cell-derived cytokines synergistically interact to drive synovial fibroblast invasive function and metabolic capacity."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "IL-1β/TGF-β synergistically drive a pathogenic RA-FLS phenotype in RA, blockade of which reduces inflammatory and invasive mechanisms."
      explanation: >-
        Provides the inflammatory challenge and comparator blockade for testing
        whether quiescence induction can suppress pathogenic RA-FLS behavior.
- discussion_id: gap_ra_hypoxia_glycolysis_lactate_axis
  prompt: >-
    How do hypoxic microenvironment signals initiate glycolytic reprogramming in RA synovial
    cells, and via what epigenetic and inflammatory mechanisms does lactate accumulation and
    lactylation drive synovial hyperplasia, pannus formation, and osteoclastic bone destruction?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Inflammatory Cytokine Production
  - pathophysiology#Synovial Hyperplasia
  - pathophysiology#Cartilage and Bone Destruction
  rationale: >-
    RA synovitis is characterized by a hypoxic microenvironment driven by chronic inflammation,
    increased metabolic demand, and impaired oxygen diffusion. Recent literature identifies that
    hypoxia → glycolytic switching → lactate-mediated epigenetic signaling (lactylation) as a
    conserved axis driving RA pathology. However, the specific causal relationships remain incompletely
    characterized: (1) which synovial cell types (fibroblasts, macrophages, T cells) are primary targets
    of hypoxic glycolytic reprogramming, (2) how lactate and lactylation of histone and non-histone
    proteins modify inflammatory gene expression, and (3) how metabolic reprogramming mechanistically drives
    the progression from inflammatory cytokine secretion to synovial hyperplasia and invasive pannus formation
    with subsequent cartilage and bone erosion. The RA entry captures autoimmune and inflammatory cytokine
    drivers but lacks representation of this metabolic-epigenetic axis as a mechanistic complement to classical
    immune-centered models, with both conserved cell-intrinsic and synovial-niche implications for targeting
    either the glycolytic program, lactate metabolism, or lactate-dependent epigenetic rewiring.
  evidence:
  - reference: PMID:42346149
    reference_title: "Mechanisms and Therapeutic Targets of Hypoxia-Mediated Modifications in Glycolysis and Lactylation in Rheumatoid Arthritis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In an inflammatory environment, the body's metabolic rate accelerates, leading to increased local
      oxygen consumption and ultimately creating a hypoxic microenvironment. Research has shown that under
      hypoxic conditions, glycolysis serves as the body's primary energy pathway and is essential for sustaining
      the inflammatory response. Furthermore, lactate, a byproduct of glycolysis, functions not only as a metabolic
      byproduct but also as a precursor molecule; through lactylation, it contributes to the progression of RA.
    explanation: >-
      Recent review articulates the hypoxia-glycolysis-lactylation axis as an incompletely characterized but
      potentially conserved driver of RA pathology, mechanistically distinct from classical autoimmune pathways.
disease_term:
  preferred_term: rheumatoid arthritis
  term:
    id: MONDO:0008383
    label: rheumatoid arthritis
gene_sets:
- gene_set: MYGENESET:KEGG_RHEUMATOID_ARTHRITIS
  relationship: CANONICAL_PATHWAY
  note: >-
    KEGG rheumatoid arthritis pathway.
classifications:
  harrisons_chapter:
  - classification_value: IMMUNE_RHEUMATOLOGIC
    evidence:
    - reference: PMID:28451788
      reference_title: "The role of autoantibodies in the pathophysiology of rheumatoid arthritis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation."
      explanation: Peer-reviewed review explicitly characterises RA as an autoimmune joint disease, supporting the Harrison's Immune-Mediated, Inflammatory, and Rheumatologic classification.

📚

References & Deep Research

Deep Research

Disorder ▸

Disorder

Name: Rheumatoid Arthritis
Category: Complex
Existing deep-research providers: falcon
Existing evidence reference count in YAML: 135

Key Pathophysiology Nodes

Autoimmune Response
Inflammatory Cytokine Production
Synovial Hyperplasia
Cartilage and Bone Destruction
JAK/STAT Signaling
NF-κB Activation
Neutrophil Extracellular Trap Formation
B Cell and Plasma Cell Responses
Mucosal Origins and Dysbiosis
Epigenetic Dysregulation of T Cell Function
Deep research literature mapping

Citation Inventory (for evidence mapping)

DOI:10.1007/s11926-023-01129-2
DOI:10.1007/s11926-024-01135-y
DOI:10.1038/s41584-024-01154-0
DOI:10.3390/cells13090743
DOI:10.4078/jrd.2024.0151

Falcon ▸

Pathophysiology description

Edison Scientific Literature 16 citations 2025-12-15T09:09:47.517226

Pathophysiology description Rheumatoid arthritis is a systemic autoimmune disease characterized by a breakdown of tolerance to post-translationally modified self-antigens (notably citrullinated proteins) and by chronic synovitis with stromal remodeling. Contemporary models converge on mucosal origins in subsets of patients: aberrant immune activation in lung, oral, and gut mucosa (linked to dysbiosis, epithelial barrier dysfunction, and local citrullination) precedes and drives systemic autoimmunity with IgA-class autoantibodies (ACPA, RF) and eventually joint-localized synovitis (Holers et al., 2024) (holers2024distinctmucosalendotypes pages 21-23). Synovial tissue single-cell and spatial studies define heterogeneous inflammatory states marked by pathogenic macrophage and fibroblast programs, T peripheral helper (Tph) cells that sustain B-cell responses, and ectopic lymphoid activation, underpinned by genetic risk centered on HLA-DRB1 shared-epitope alleles presenting citrullinated epitopes to CD4+ T cells (Jonsson, 2024) (jonsson2024synovialtissueinsights pages 9-11).

Core mechanisms - Adaptive autoimmunity and HLA–peptide presentation: HLA-DRB1 shared epitope (SE) alleles preferentially present citrullinated peptides to CD4+ T cells, providing a genetic scaffold for ACPA-positive disease; mucosal priming and epitope spreading are hallmarks in pre-RA (Jonsson, 2024; Holers et al., 2024) (jonsson2024synovialtissueinsights pages 9-11, holers2024distinctmucosalendotypes pages 21-23). - Mucosal origins and microbiome: RA-related autoantibodies and mucosal immune activation are detected in lung/oral/gut mucosa before arthritis; mechanistic links include bacterial PAD (Porphyromonas gingivalis) and LtxA (Aggregatibacter actinomycetemcomitans)–induced neutrophil hypercitrullination; Prevotella copri and metabolite pathways (e.g., indoles) modulate Th17 responses and disease penetrance (Seymour et al., 2024) (seymour2024microbialmechanismsof pages 1-3, seymour2024microbialmechanismsof pages 12-13). Notably, a large 2024 quantitative profiling study in at-risk first-degree relatives found no stage-specific gut microbiome signature overall, underscoring cohort heterogeneity (RMD Open 2024, Gilbert et al., summarized in Holers 2024) (holers2024distinctmucosalendotypes pages 21-23). - Innate immunity and citrullination sources: Neutrophil extracellular traps (NETs) release citrullinated histones and autoantigens; platelets and monocytes add to the antigenic pool via PAD expression and surface PAD4 activity; citrullination of complement C1 inhibitor (C1-INH) impairs complement regulation (Seymour et al., 2024) (seymour2024microbialmechanismsof pages 1-3, seymour2024microbialmechanismsof pages 12-13). These processes interface with stromal and adaptive responses in synovium (Jonsson, 2024) (jonsson2024synovialtissueinsights pages 9-11). - Synovial stromal and myeloid circuits: Perivascular Notch/TGF-β–patterned fibroblast niches (including COMPhi fibrogenic states) and SPP1+ macrophages sustain inflammation and remodeling; Tph cells drive B-cell/plasma cell responses and ectopic lymphoid structures (Jonsson, 2024) (jonsson2024synovialtissueinsights pages 9-11).

Dysregulated pathways - JAK/STAT: Central conduit for IL-6 and interferon signaling; clinical targeting (JAK inhibitors) validates pathogenic relevance in both immune and stromal compartments (Ghang et al., 2025 overview citing 2023–2024 primary work) (ghang2025currentstateand pages 1-3). - TNF/IL-6/IL-17 and NF-κB: Canonical inflammatory axes sustaining synovitis and systemic features (Ghang et al., 2025; Jonsson, 2024) (ghang2025currentstateand pages 1-3, jonsson2024synovialtissueinsights pages 9-11). - PI3K/AKT/mTOR and MAPK/ERK: Drive fibroblast-like synoviocyte (FLS) proliferation, invasiveness, and cytokine production; integrate TNF/IL-1 signals (Jonsson, 2024; Ghang et al., 2025) (jonsson2024synovialtissueinsights pages 9-11, ghang2025currentstateand pages 1-3). - cGAS–STING: DNA-sensing innate pathway implicated in synovial IFN programs and chronic inflammation (Ghang et al., 2025) (ghang2025currentstateand pages 1-3).

Disease progression (sequence of events) 1) Mucosal priming: Dysbiosis, PAD/LtxA-triggered hypercitrullination, barrier dysfunction; emergence of IgA ACPA/RF; mucosal Th17/Tph polarization (Holers et al., 2024; Seymour et al., 2024) (holers2024distinctmucosalendotypes pages 21-23, seymour2024microbialmechanismsof pages 1-3). 2) Systemic autoimmunity: Affinity maturation and epitope spreading of ACPA; HLA-DRB1 SE–restricted CD4+ T-cell responses to citrullinated epitopes; circulating immune complexes (Holers et al., 2024) (holers2024distinctmucosalendotypes pages 21-23). 3) Articular localization: Recruitment of myeloid cells; NETosis and monocyte/macrophage activation; FLS activation via TNF/IL‑1/IL‑6/NF‑κB and PI3K/AKT/MAPK cascades; ectopic lymphoid structures and plasma cell accrual (Jonsson, 2024) (jonsson2024synovialtissueinsights pages 9-11). 4) Chronicity/remodeling: SPP1+ macrophage–fibroblast–T cell circuits, perivascular TGF‑β/Notch niches (COMPhi) drive persistent inflammation and fibrosis; osteoclastogenesis causes erosions (Jonsson, 2024) (jonsson2024synovialtissueinsights pages 9-11).

Key Molecular Players - Genes/Proteins (HGNC): HLA‑DRB1 (shared epitope); PADI4/PADI2 (citrullination enzymes); IL6R (IL‑6 signaling); TNF (master cytokine); JAKs/TYK2 (JAK/STAT conduit) (Jonsson, 2024; Holers, 2024; Ghang, 2025) (jonsson2024synovialtissueinsights pages 9-11, holers2024distinctmucosalendotypes pages 21-23, ghang2025currentstateand pages 1-3). - Chemical Entities (CHEBI/Concepts): Citrullinated peptides; platelet microparticles carrying citrullinated proteins; complement C1‑INH (citrullinated) (Seymour, 2024) (seymour2024microbialmechanismsof pages 1-3, seymour2024microbialmechanismsof pages 12-13). - Cell Types (CL): Fibroblast-like synoviocytes (perivascular, COMPhi); SPP1+ macrophages; Tph CD4+ cells; B cells/plasma cells; neutrophils (NETs); monocytes/osteoclast precursors (Jonsson, 2024) (jonsson2024synovialtissueinsights pages 9-11). - Anatomical Locations (UBERON): Lung, gut, oral mucosa (mucosal endotypes); synovium (Holers, 2024; Jonsson, 2024) (holers2024distinctmucosalendotypes pages 21-23, jonsson2024synovialtissueinsights pages 9-11).

Biological Processes (GO) disrupted - Antigen processing/presentation via MHC class II; cytokine-mediated signaling (JAK/STAT); NF‑κB activation; cell proliferation/migration (PI3K/AKT/mTOR; MAPK/ERK); DNA sensing (cGAS–STING); neutrophil degranulation/NET formation; complement regulation (citrullinated C1‑INH) (Ghang 2025; Jonsson 2024; Seymour 2024; Holers 2024) (ghang2025currentstateand pages 1-3, jonsson2024synovialtissueinsights pages 9-11, seymour2024microbialmechanismsof pages 1-3, holers2024distinctmucosalendotypes pages 21-23, seymour2024microbialmechanismsof pages 12-13).

Cellular Components - Cell surface HLA‑DR peptide-binding groove (shared epitope); nuclear/cytosolic PAD localization and extracellular exposure on monocyte surfaces; extracellular traps (NETs); perivascular synovial niches with endothelial–fibroblast Notch crosstalk; platelet-derived microparticles in synovial/extracellular space; complement components in plasma/synovial fluid (Jonsson, 2024; Seymour, 2024) (jonsson2024synovialtissueinsights pages 9-11, seymour2024microbialmechanismsof pages 1-3, seymour2024microbialmechanismsof pages 12-13).

Phenotype associations (HP) - Chronic symmetric polyarthritis with morning stiffness, synovial hypertrophy, joint erosions; extra-articular mucosal and pulmonary involvement in subsets (Holers, 2024; Jonsson, 2024) (holers2024distinctmucosalendotypes pages 21-23, jonsson2024synovialtissueinsights pages 9-11).

Expert opinions and 2023–2024 developments - Mucosal endotypes: Holers et al. (2024) propose distinct mucosal trajectories (lung, gut, oral) that initiate/drive RA and emphasize that IgA autoimmunity, airway abnormalities, and mucosa-derived immune responses can precede joint disease; dietary fiber/SCFA and indole pathways modulate systemic inflammation (with mechanistic preclinical support) (holers2024distinctmucosalendotypes pages 21-23). - Synovial heterogeneity: Jonsson (2024) summarizes single-cell/spatial insights—B cell–rich synovitis and macrophage/fibroblast niches predict therapeutic responses and highlight Notch/TGF‑β patterning, SPP1+ macrophages, and Tph cells as actionable axes (jonsson2024synovialtissueinsights pages 9-11). - Microbiome mechanisms: Seymour et al. (2024) synthesize bacterial PAD/LtxA-driven hypercitrullination, molecular mimicry (e.g., P. copri antigens), microbial translocation (e.g., Fusobacterium OMVs), and metabolite-immune interactions; importantly, not all cohorts show consistent dysbiosis signals (seymour2024microbialmechanismsof pages 1-3, seymour2024microbialmechanismsof pages 12-13).

Relevant statistics and data - Progression risk: In ACPA-positive individuals, ~40–60% progress to RA over 2–5 years, often with mucosal IgA autoantibodies preceding disease (Seymour 2024; citing cohort data within review) (seymour2024microbialmechanismsof pages 1-3). - Microbiome null findings: A 2024 study of 371 first-degree relatives at preclinical stages found no significant quantitative microbiome profile differences across disease stages (PERMANOVA R2≈0.008, p=0.56), tempering generalizations about universal dysbiosis signatures (as summarized in Holers 2024) (holers2024distinctmucosalendotypes pages 21-23). - Synovial stratification and therapy: B cell–rich synovitis associates with better rituximab response, whereas B cell–poor/inflammatory pathotypes may favor IL‑6 receptor blockade (tocilizumab) (Jonsson 2024) (jonsson2024synovialtissueinsights pages 9-11).

Evidence items with PMIDs/URLs (selection; 2023–2024 priority) - Holers VM et al. Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis. Nat Rev Rheumatol. 2024 Sep;20(10):601–613. doi:10.1038/s41584-024-01154-0. https://doi.org/10.1038/s41584-024-01154-0 (holers2024distinctmucosalendotypes pages 21-23). - Jonsson AH. Synovial Tissue Insights into Heterogeneity of Rheumatoid Arthritis. Curr Rheumatol Rep. 2024 Dec;26:81–88. doi:10.1007/s11926-023-01129-2. https://doi.org/10.1007/s11926-023-01129-2 (jonsson2024synovialtissueinsights pages 9-11). - Seymour BJ, Allen BE, Kuhn KA. Microbial Mechanisms of Rheumatoid Arthritis Pathogenesis. Curr Rheumatol Rep. 2024 Feb;26:124–132. doi:10.1007/s11926-024-01135-y. https://doi.org/10.1007/s11926-024-01135-y (seymour2024microbialmechanismsof pages 1-3). - Seymour BJ et al. (mechanistic details on PAD/LtxA, mimicry, metabolites) (seymour2024microbialmechanismsof pages 12-13). - Ghang B et al. Current state and future directions of basic research in rheumatoid arthritis. J Rheum Dis. 2025;32:166–181. doi:10.4078/jrd.2024.0151 (overview integrating 2023–2024 insights). https://doi.org/10.4078/jrd.2024.0151 (ghang2025currentstateand pages 1-3).

Ontology-linked annotations - Gene/protein (HGNC): HLA‑DRB1; PADI4; PADI2; IL6R; TNF; JAK1/JAK2/TYK2 (jonsson2024synovialtissueinsights pages 9-11, holers2024distinctmucosalendotypes pages 21-23, ghang2025currentstateand pages 1-3). - Biological process (GO): “cytokine-mediated signaling pathway”; “positive regulation of NF‑κB transcription factor activity”; “phosphatidylinositol 3-kinase signaling”; “MAPK cascade”; “DNA sensing via cGAS–STING”; “neutrophil extracellular trap formation”; “antigen processing and presentation of peptide antigen via MHC class II”; “complement activation, classical pathway” (jonsson2024synovialtissueinsights pages 9-11, ghang2025currentstateand pages 1-3, seymour2024microbialmechanismsof pages 1-3, seymour2024microbialmechanismsof pages 12-13, holers2024distinctmucosalendotypes pages 21-23). - Cell types (CL): fibroblast-like synoviocytes; macrophage SPP1+ subset; neutrophil; monocyte; osteoclast; T peripheral helper (Tph); B cell; plasma cell (jonsson2024synovialtissueinsights pages 9-11, seymour2024microbialmechanismsof pages 1-3). - Anatomical locations (UBERON): synovial membrane; lung; oral mucosa; intestinal mucosa (holers2024distinctmucosalendotypes pages 21-23, jonsson2024synovialtissueinsights pages 9-11). - Chemical entities (CHEBI/concepts): citrullinated peptides; platelet microparticles; complement C1 inhibitor (citrullinated) (seymour2024microbialmechanismsof pages 1-3, seymour2024microbialmechanismsof pages 12-13). - Phenotypes (HP): HP:0001371 (Arthritis); HP:0000988 (Morning stiffness); HP:0011800 (Erosive arthritis); HP:0002093 (Interstitial lung disease) (contextualized in mucosal endotype subsets) (holers2024distinctmucosalendotypes pages 21-23, jonsson2024synovialtissueinsights pages 9-11).

Applications and real-world implementations - Precision stratification: Synovial biopsy and scRNA/spatial signatures (B cell–rich pathotype, SPP1+ macrophages, COMPhi fibroblasts) may inform biologic choice (rituximab vs. tocilizumab) and identify fibrosis-prone, treatment-resistant niches (Jonsson, 2024) (jonsson2024synovialtissueinsights pages 9-11). - Mucosal risk interception: Monitoring IgA ACPA/RF and mucosal imaging/biomarkers in at-risk individuals; dietary fiber/SCFA modulation and periodontal care are being explored to mitigate mucosal drivers (Holers, 2024) (holers2024distinctmucosalendotypes pages 21-23). - Targeted signaling blockade: JAK inhibitors and IL‑6/TNF blockade remain effective across phenotypes, underlining pathway centrality (Ghang, 2025 integrating recent trials and mechanistic data) (ghang2025currentstateand pages 1-3).

Included artifact | Category | Item | Ontology namespace tag | Role/Mechanism | 2023–2024 Evidence | |---|---|---|---|---| | Genetic risk | HLA-DRB1 shared epitope | HGNC | Presents citrullinated peptides to CD4+ T cells; major seropositive RA risk allele driving ACPA-associated immunity. | (jonsson2024synovialtissueinsights pages 9-11, ghang2025currentstateand pages 1-3) | | Enzyme (citrullination) | PADI4 | HGNC | Catalyzes protein citrullination in NETs/METs and immune cells → generates ACPA-target neoepitopes. | (seymour2024microbialmechanismsof pages 1-3, seymour2024microbialmechanismsof pages 12-13, barbera2025theroleof pages 7-11) | | Enzyme (citrullination) | PADI2 | HGNC | Contributes to citrullination at mucosal sites and in inflammatory cells; complements PAD4 in antigen generation. | (seymour2024microbialmechanismsof pages 12-13, barbera2025theroleof pages 7-11) | | Cytokine receptor | IL6R | HGNC | Mediates IL-6 signaling (JAK/STAT) driving systemic and synovial inflammation; therapeutic target (tocilizumab). | (ghang2025currentstateand pages 1-3, jonsson2024synovialtissueinsights pages 9-11) | | Cytokine | TNF | HGNC | Central proinflammatory driver of synovitis, FLS activation and leukocyte recruitment; target of TNF inhibitors. | (ghang2025currentstateand pages 1-3, jonsson2024synovialtissueinsights pages 9-11) | | Signaling pathway | TYK2 / JAK-STAT | GO | Intracellular route for cytokine signals (IL-6, IFNs); dysregulated in RA and targeted by JAK inhibitors. | (ghang2025currentstateand pages 1-3, barbera2025theroleof pages 7-11) | | Signaling pathway | NF-κB signaling | GO | Transcriptional hub for proinflammatory cytokines and survival signals in immune/fibroblast cells. | (ghang2025currentstateand pages 1-3, barbera2025theroleof pages 7-11) | | Signaling pathway | PI3K/AKT/mTOR | GO | Promotes FLS proliferation, survival and invasive phenotype; implicated in synovial hyperplasia. | (jonsson2024synovialtissueinsights pages 9-11, ghang2025currentstateand pages 1-3) | | Signaling pathway | MAPK/ERK | GO | Regulates cytokine production and FLS responses contributing to synovitis and tissue damage. | (ghang2025currentstateand pages 1-3, barbera2025theroleof pages 7-11) | | Innate sensing | cGAS–STING pathway | Pathway | DNA-sensing innate pathway implicated in synovial type-I IFN and inflammatory responses in arthritis. | (barbera2025theroleof pages 7-11, ghang2025currentstateand pages 1-3) | | Stromal niche | Fibroblast-like synoviocytes — perivascular COMPhi / TGF-β–Notch niche | CL / UBERON | Perivascular COMPhi fibroblasts form TGF-β gradients (Notch-regulated) driving fibrogenic remodeling and treatment resistance. | (jonsson2024synovialtissueinsights pages 9-11) | | Myeloid subset | Macrophage SPP1+ subset | CL | Pathogenic synovial macrophage subset that communicates with T cells and fibroblasts to sustain inflammation. | (jonsson2024synovialtissueinsights pages 9-11, seymour2024microbialmechanismsof pages 12-13) | | T cell subset | T peripheral helper (Tph) cells | CL | Provide B-cell help in synovium (CXCL13/IL-21) promoting local ACPA-producing plasma cells and ectopic responses. | (jonsson2024synovialtissueinsights pages 9-11, ghang2025currentstateand pages 1-3) | | Lymphoid structures | B cells / plasma cells & ectopic lymphoid structures | CL | Local antibody generation (ACPA, RF) within synovium/mucosa; predicts response to B-cell targeted therapy. | (jonsson2024synovialtissueinsights pages 9-11, perera2024clinicalphenotypesserological pages 20-21) | | Innate effector | Neutrophils & NETs | CL / GO | NETosis (PAD4-driven) releases citrullinated antigens and DAMPs that amplify autoimmunity and synovial inflammation. | (seymour2024microbialmechanismsof pages 1-3, seymour2024microbialmechanismsof pages 12-13) | | Monocyte lineage | Monocytes → Osteoclastogenesis | CL / GO | Monocyte-derived osteoclast differentiation (RANKL-driven) mediates bone erosion; monocyte activation linked to HLA-SE. | (ghang2025currentstateand pages 1-3, jonsson2024synovialtissueinsights pages 9-11) | | Complement regulation | Complement C1 inhibitor — citrullination | CHEBI / GO | Citrullination of C1-INH impairs complement/contact system regulation, increasing inflammatory complement activity. | (seymour2024microbialmechanismsof pages 12-13, ghang2025currentstateand pages 1-3) | | Extracellular vesicles | Platelet microparticles with citrullinated autoantigens | CHEBI | Platelet-derived microparticles contain PAD4 and citrullinated proteins that can be ACPA targets and activate immunity. | (seymour2024microbialmechanismsof pages 1-3, seymour2024microbialmechanismsof pages 12-13) | | Cell-surface enzyme | Monocyte surface PAD4 | HGNC / Cell surface | Active PAD4 displayed on monocyte surfaces citrullinates extracellular proteins, creating neoantigens at cell interface. | (jonsson2024synovialtissueinsights pages 9-11, seymour2024microbialmechanismsof pages 1-3) | | Mucosal sites | Mucosal endotypes: lung, gut, oral | UBERON | Sites of early citrullination, mucosal inflammation and immune priming; mucosal dysbiosis can precede clinical RA. | (holers2024distinctmucosalendotypes pages 21-23, seymour2024microbialmechanismsof pages 1-3, ghang2025currentstateand pages 1-3) | | Microbiome signals | Prevotella copri; Porphyromonas gingivalis; Aggregatibacter actinomycetemcomitans | Taxon / Concept | Microbial taxa implicated in dysbiosis, citrullination (PPAD/LtxA), molecular mimicry and metabolite-driven immune modulation. | (seymour2024microbialmechanismsof pages 1-3, seymour2024microbialmechanismsof pages 12-13) | | Cytokine circuit | OSM–OSMR macrophage–fibroblast circuit | Pathway / cytokine | Oncostatin M from macrophages activates OSMR+ fibroblasts generating inflammatory and tissue-destructive programs targeted by JAKi. | (jonsson2024synovialtissueinsights pages 9-11, barbera2025theroleof pages 7-11) |

Table: Compact reference table mapping core molecular/cellular entities, ontologies, brief mechanisms, and 2023–2024 supporting evidence (context IDs) to aid rapid curation and knowledgebase annotation.

Direct quotes (supporting statements) - “Evidence suggests that self-tolerance is breached at mucosal sites… Primary sites studied include the lung, gut and oral mucosa” (Holers 2024) (holers2024distinctmucosalendotypes pages 21-23). - “Synovial tissue single-cell studies revealed T peripheral helper cells, macrophage subsets, and Notch-shaped fibroblast niches that underpin RA heterogeneity and may predict therapeutic response” (Jonsson 2024) (jonsson2024synovialtissueinsights pages 9-11). - “Periodontal and enteric pathobionts… produce PAD or leukotoxins that induce hypercitrullination and molecular mimicry, linking dysbiosis to ACPA generation” (Seymour 2024) (seymour2024microbialmechanismsof pages 1-3, seymour2024microbialmechanismsof pages 12-13).

Limitations and open questions - Not all cohorts demonstrate consistent gut dysbiosis signatures in pre-RA; host genetics, geography, and exposures likely stratify mucosal endotypes (Holers 2024) (holers2024distinctmucosalendotypes pages 21-23). - Mechanistic dissection of cGAS–STING in human RA synovia remains an area of active investigation (Ghang 2025) (ghang2025currentstateand pages 1-3).

URLs and dates are provided above alongside each citation. All claims are supported by recent primary/review sources, prioritizing 2023–2024 publications, with integrative context drawn from 2025 overviews where necessary to frame 2023–2024 findings (holers2024distinctmucosalendotypes pages 21-23, jonsson2024synovialtissueinsights pages 9-11, seymour2024microbialmechanismsof pages 1-3, seymour2024microbialmechanismsof pages 12-13, ghang2025currentstateand pages 1-3).

References

(holers2024distinctmucosalendotypes pages 21-23): V. Michael Holers, Kristen M. Demoruelle, Jane H. Buckner, Eddie A. James, Gary S. Firestein, William H. Robinson, Allen C. Steere, Fan Zhang, Jill M. Norris, Kristine A. Kuhn, and Kevin D. Deane. Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis. Nature reviews. Rheumatology, 20:601-613, Sep 2024. URL: https://doi.org/10.1038/s41584-024-01154-0, doi:10.1038/s41584-024-01154-0. This article has 29 citations.
(jonsson2024synovialtissueinsights pages 9-11): Anna Helena Jonsson. Synovial tissue insights into heterogeneity of rheumatoid arthritis. Current rheumatology reports, 26:81-88, Dec 2024. URL: https://doi.org/10.1007/s11926-023-01129-2, doi:10.1007/s11926-023-01129-2. This article has 18 citations and is from a peer-reviewed journal.
(seymour2024microbialmechanismsof pages 1-3): Brenda J. Seymour, Brendan E. Allen, and Kristine A. Kuhn. Microbial mechanisms of rheumatoid arthritis pathogenesis. Current rheumatology reports, 26:124-132, Feb 2024. URL: https://doi.org/10.1007/s11926-024-01135-y, doi:10.1007/s11926-024-01135-y. This article has 14 citations and is from a peer-reviewed journal.
(seymour2024microbialmechanismsof pages 12-13): Brenda J. Seymour, Brendan E. Allen, and Kristine A. Kuhn. Microbial mechanisms of rheumatoid arthritis pathogenesis. Current rheumatology reports, 26:124-132, Feb 2024. URL: https://doi.org/10.1007/s11926-024-01135-y, doi:10.1007/s11926-024-01135-y. This article has 14 citations and is from a peer-reviewed journal.
(ghang2025currentstateand pages 1-3): Byeongzu Ghang, Jin Kyun Park, Ji Hyeon Ju, and Seungwoo Han. Current state and future directions of basic research in rheumatoid arthritis. Journal of Rheumatic Diseases, 32:166-181, Feb 2025. URL: https://doi.org/10.4078/jrd.2024.0151, doi:10.4078/jrd.2024.0151. This article has 1 citations.
(barbera2025theroleof pages 7-11): L LA BARBERA. The role of jak/stat inhibition in modulating the innate immune response in patients with rheumatoid arthritis. Unknown journal, 2025.
(perera2024clinicalphenotypesserological pages 20-21): James Perera, Chiara Aurora Delrosso, Alessandra Nerviani, and Costantino Pitzalis. Clinical phenotypes, serological biomarkers, and synovial features defining seropositive and seronegative rheumatoid arthritis: a literature review. Cells, 13:743, Apr 2024. URL: https://doi.org/10.3390/cells13090743, doi:10.3390/cells13090743. This article has 33 citations and is from a poor quality or predatory journal.

Ask OpenScientist

OpenScientist Report

Classifications

Definitions

Subtypes

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Biochemical Markers

Differential Diagnoses

Source YAML

References & Deep Research

Deep Research

Disorder

Key Pathophysiology Nodes

Citation Inventory (for evidence mapping)